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IForeword and User’s Guide
INTRODUCTION
1
1. FOREWORD AND USER’S GUIDE
There is now a large body of evidence available to link nociception with subsequent alter-
ations in nervous system function, both peripheral and central (1,2). In various animal
models, studies have not only proven the existence of this link, but they have also pro-
vided a large amount of detail on the nature of and the mechanisms underlying these
changes (3). Such nociceptive neuroplasticity, particularly that of central nervous system
processing, is presently considered to be an important factor in the aetiology of pain after
nociception, and has been suggested to play a significant role in subsequent acute and
chronic pain outcomes (1,3,4). It should be noted at this point that in this book we will
use the term neuroplasticity in the broad sense, and that it thus includes both functional
and structural changes in nervous system function.
A large variety of animal models, both non-intact and intact, have been developed to pro-
vide valuable information on the mechanisms underlying pain and nociception (5-7). In
this context, the most frequently studied species are rodents, particularly rats. Non-intact
models are frequently either decerebrate or spinalised and are most useful for studying
specific aspects of nociception. They may include neuroelectrophysiological elements
such as single-neurone electrode recordings as well as various histobiochemical and sim-
ilar techniques to understand biochemical and biomolecular aspects of the nociceptive
process. This type of model also includes those with specific lesions in the central nerv-
ous system in order to better understand the pathways involved in pain and nociception
processing. Intact models provide valuable information on the holistic, integrated
response to nociception. In addition to electrophysiological and histobiochemical infor-
mation of the type also obtained in non-intact models, intact models permit the observa-
tion of behavioural responses, which are regarded by some as providing surrogate mod-
els for human pain behaviour and experience. Intact animal models have also proven
invaluable in the study of pathological pain states. Here, a disease state similar to a
painful human disease state is induced, and thus mechanisms as well as effects of thera-
peutic interventions can be studied. Examples of such models include experimental
monoarthritis, colitis or neuropathy, induced by the introduction of irritant material into
(or near) joint, colon or large peripheral nerve. Several animal models of surgical pain,
e.g. by incision (8), have now also been developed.
In animal models, the pattern of neuroplasticity following nociception is complex, varying
with regard to time (e.g. acute vs. chronic), anatomical location (e.g. spinal vs. supraspinal
systems), and nature (e.g. excitation vs. inhibition) (1,3,9,10). In the context of basic ani-
mal research, a considerable, albeit still far from complete, understanding of the biomolec-
ular mechanisms involved in the response to nociception has been achieved (e.g. 1,3,11). In
the animal model, it is now proving increasingly possible to link this understanding of
nociceptive biomolecular mechanisms to our higher-order understanding of the neuro-
physiological changes accompanying nociception (i.e. nociceptive neuroplasticity). This
linkage has been the basis of most of the pharmacological research in the field of pain of the
8
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last 10-15 years, as it provides the connection between biomolecular mechanisms amenable
to pharmacological modulation and neurophysiological changes considered relevant to the
clinical phenomenon of pain (1,3,4). Thus the discovery and exploration of post-nocicep-
tive neuroplasticity has provided - at least theoretically - the basis for a rational, mecha-
nism-based approach to pain therapeutics and management (12-14).
The practical application of this discovery to clinical pain practice is desirable because
the present symptom-based approach to pain treatment has clearly reached its limits, as
illustrated by the significant numbers of pain patients, both chronic and acute, still not
achieving satisfactory analgesia (15-18). The transfer of mechanism-based management -
based on animal model results - to clinical practice has, however, proven difficult. This is
demonstrated by the discussion surrounding one of the better-known postulates to result
from the concept of nociceptive neuroplasticity, namely the postulate of pre-emptive
analgesia for pain after surgery (1,4,12,13). One reason for this apparent transfer failure
from basic to clinical science is surely the inherent difficulty of extrapolating from exper-
imental animal data to the human clinical situation. A much more fundamental reason is
likely to be the - generally unstudied and unproven - assumption that the nociceptive
neuroplasticity demonstrated in animal studies can be equated with (or even reflected by)
the subjective pain experience of a human patient as measured by pain scores or analgesic
consumption (5,13). Both of these reasons make the collection - in the research and clin-
ical setting - of direct measures of neuroplasticity in the human necessary and unavoid-
able as the basis for a transfer to clinical mechanism-based pain management. 
In the context of human surgery, data as to the nature and course of neuroplasticity after
surgical nociception remain sparse. Little is known about the relationship between meas-
ures of neuroplasticity (e.g. psychophysical measures) and measures of the patient’s pain
experience (e.g. pain scores, analgesic use), and the effects of clinically typical and rele-
vant factors such as analgesia or pre-existing pain on nociceptive neuroplasticity are
largely uninvestigated. The aim of this work is thus to provide a first basis for a transfer
from symptom-orientated to mechanism-based pain management by validating the use of
nociceptive neuroplasticity as an objective, clinically usable endpoint in the context of
surgical pain and nociception. 
The current work will address this aim in a number of ways. Firstly, we will present an
integrated review of the theoretical background, particularly of knowledge from basic
animal research, on nociception, biomolecular mechanisms, neuroplasticity and pain,
with special emphasis on linking these phenomena. Secondly, based on our research, we
will offer evidence validating neuroplasticity, as measured by quantitative sensory test-
ing (QST), for quantifying both analgesia and nociception. Demonstrating that such QST
use is feasible for clinical application will form a third thrust of the present work. Finally,
we will provide an overview of the new information which application of QST-measured
nociceptive neuroplasticity has brought in the context of our research. This overview will
give insight into the real potential which nociceptive neuroplasticity has as a new, objec-
9
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tive endpoint providing novel information unobtainable via current subjective measures,
and thus for altering the way we practice perioperative pain and nociception manage-
ment.
This book is structured as follows. The background section provides the theoretical (chap-
ter 2) and practical (chapter 3) background to the topic under discussion, closing with an
exposition of the overall goals of the research to be presented (chapter 4). In the subse-
quent two studies sections, we present our own research in this area. Each section con-
tains an introduction to the topic which also includes a more detailed listing of the ques-
tions to be investigated by the research presented (chapters 5 and 9). The articles cover-
ing our research then follow. Each section is completed by a summary of the research pre-
sented (chapters 8 and 16), containing a specific listing of the answers to the questions
posed in the introduction. Two published review articles (chapters 17 and 18) covering
controversies and clinical practice in this field are presented in the next section. The final
section presents an overview discussion (chapter 19) of the implications of our research for
surgical pain management today together with an outlook for the future.
10
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II
Theory - Linking Nociception to Neuroplasticity
Practice - Measuring Nociceptive Neuroplasticity in the Clinical Context 
Study Goals - QST, Analgesia and Surgical Nociceptive Neuroplasticity
BACKGROUND
2
3
4
2. THEORY - LINKING NOCICEPTION TO NEUROPLASTICITY
Two decades ago, the “classic” view of pain and nociception was still predominantly that
of a hard-wired nervous system responding in a fixed way to various nociceptive inputs.
Thus, noxious stimulation causes specific peripheral nociceptors to fire, with the signal
then being passed on to the spinal cord by A-delta or C-fibre primary nociceptive affer-
ent nerves. These fibres then terminate in a specific, highly spatially organised fashion in
the spinal posterior horn, where they then synapse with second order neurons project-
ing up into the brain. After crossing the midline, these second order pain fibres enter the
spinothalamic tract, located anterolaterally, traverse the brainstem in the lateral white
funiculus and terminate - again in a highly somatotopically organised fashion - in the ven-
troposterolateral nucleus of the thalamus. Here, synaptic transmission again takes place
onto third order nerve fibres, which then project on to sensory cortex, also in a somato-
topically organised fashion. Since this time, it has become abundantly clear that pain pro-
cessing and its pathologies cannot be explained within the context of a hard-wired neu-
ral processing system. What has emerged instead is the understanding that nociceptive
input itself changes the way the pain and nociception-processing nervous system behaves
and is wired. Thus nociceptive input alters the way the nervous system behaves at every
level - peripheral, spinal and supraspinal - with quantity and quality of these changes
depending not only on the quantity and quality of the nociceptive input but also on the
vulnerability of the individual nervous system to such input. 
Any discussion of the connection between nociceptive input (nociception) and resulting
alterations to nervous system sensory processing (neuroplasticity) must cover both the
neurophysiological changes taking place as well as the biomolecular mechanisms pro-
ducing them. This then makes it possible to link particular effects on the nociceptive neu-
roplastic response with defined pharmacological interventions affecting nociceptive bio-
molecular mechanisms, thus providing the objective diagnostic process fundamental to
the implementation of mechanism-based management strategies regarding nociception. 
To prevent misunderstanding, we also need to briefly address the difference between
nociception and pain. The pain experience by a person in response to a nociceptive input
is multifactorial in origin, and nociception is thus accompanied by many other factors in
finally determining the pain a patient subjectively experiences. However, all pain ulti-
mately has its origin in some nociceptive event, and the modulation of nociception will
always have an important - if not major - role to play in the management of pain, partic-
ularly if regarded over its entire time course. In addition, nociception is aetiologically
much closer to the metabolic and immunological consequences of a noxious stimulus than
pain is, making measures of nociceptive load much better candidates as surrogate disease
outcome endpoints than measures of pain. 
14
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The aim of this chapter is thus to provide, based on animal studies over the last 10-15
years, an overview of the biomolecular mechanisms underlying the three main dimen-
sions of the integrated neuroplastic response to nociception, namely its nature (i.e. exci-
tatory vs. inhibitory), anatomical substrate (i.e. peripheral vs. spinal vs. supraspinal), and
time course (i.e. acute vs. chronic). This will supply the theoretical grounding necessary
to link nociception, biomolecular mechanisms and neuroplasticity, and hence justify the
use of quantitative sensory testing for diagnosing nociceptive neuroplasticity as the foun-
dation of a mechanism-based approach to nociception and pain therapeutics.
2.1. Excitatory Neuroplasticity
Excitatory changes in nervous system function after nociception occur in three phases.
Already substantial and easily reversible, the first, acute phase (activation) takes place
rapidly and manifests itself as a progressive increase in the neuronal response to repeat-
ed stimulation (“activation-dependent plasticity”). The second, sub-acute phase (modu-
lation) develops - and is reversible - more slowly. Here neuronal excitability is increased
due to altered transmembrane ionophore function subsequent to phosphorylation of
receptors, ion channels and regulatory proteins (“sensitisation”). The changes in the
third, chronic phase of neuroplasticity (modification) are long-lasting, take place much
more slowly, and result in distinctly abnormal sensory processing, not only quantitative-
ly but also qualitatively. They are the consequence of altered expression of neurotrans-
mitters, receptors and ionophores with resulting disturbances in internal and external
neuronal architecture and survival. It should be emphasised that the transitions between
these three phases are fluid.
15
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Figure 1: Summary of mechanisms of excitatory neuroplasticity and its time course (from reference 4).
2.1.1. Acute Excitatory Neuroplasticity: Activation
In the periphery, the initial effect of noxious stimulation is the activation of nociceptive
transducers. These consist of receptor/ionophore complexes which depolarise (or reduce
the resting potential of) the nociceptive nerve terminal in response to specific noxious
stimuli of a chemical, thermal or mechanical nature (1-3). Activation of peripheral noci-
ceptors can be elicited both by stimuli that do (autosensitisation) or do not (heterosensi-
tisation) depolarise them, and results in a reduction of the high thresholds normally nec-
essary to depolarise nociceptors (4). If the current resulting from transduction exceeds
the membrane threshold value, an action potential follows, which is then conducted to
the spinal cord via the primary afferent nociceptive nerve fibre. 
At the spinal posterior horn, signals due to minor nociception (low intensity and frequen-
cy) are synaptically transmitted by the release of neurotransmitters, mainly acting via
alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and kainate recep-
tors, with subsequent initiation of fast excitatory postsynaptic potentials (EPSPs) which
encode stimulation onset, location, duration, and intensity (5). Activation-dependent
plasticity (here termed wind-up) occurs with prolonged, higher frequency and intensity
nociception via the generation of slow EPSPs (duration: tens of seconds), the consequence
of N-methyl-D-aspartate (NMDA) receptor stimulation by glutamate as well as neuro-
modulator (e.g. substance P; acting via NK1 or mGluR receptors) co-release (6,7).
Cumulative depolarisation, the result of temporal summation of slow EPSPs, is further
enhanced with each successive input as calcium currents increase due to accompanying
removal of Mg++ block of NMDA calcium ionophores and activation of voltage-gated
non-selective cation channels (8-10). Thus generated action potentials are passed on for
further processing to supraspinal synaptic relays (e.g. in the thalamus), believed to possess
similar characteristics of activation as those described for the spinal posterior horn,
although less investigated to date.
16
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Figure 2: Summary of mechanisms of peripheral activation (from reference 4). Abbreviations: VR1 = vanilloid recep-
tor; mDEG = proton gated degenerin Na+ ion channel; P2X3 = “fast” ATP-gated purinergic receptor.
17
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Figure 3: Summary of fast and slow mechanisms of spinal activation (from reference 4). Abbreviations: ESPS = exci-
tatory post-synaptic potential; Glu = glutamate; GABA = gamma-amino-butyric acid; AMPA = alpha-amino-3-hydroxy-
5-methyl-4-isoxazoleproprionic acid; NMDA = N-methyl-D-aspartate; KAI = kainate; NK1 = neurokinin 1; mGluR =
metabotrophic glutamate receptor; TrkB = tyrosine receptor kinase B; VGCC = voltage-gated calcium channel; Gly =
glycine; IP2 = inositol 4,5-bisphosphate; SP = substance P; P2X = ATP-gated purinergic receptor.
2.1.2. Sub-acute Excitatory Neuroplasticity: Modulation
Modulation resulting in increased excitability of neurones is considered to be the basis of
the clinical phenomena of hyperalgesia (increased response to pain stimuli) and allodynia
(normally non-painful stimuli result in pain) in the context of inflammatory or neuro-
pathic pain (11). Modulation typically involves various intracellular kinase signalling cas-
cades which phosphorylate and thus activate receptor/ionophore complexes and their
regulatory proteins. 
In the periphery, modulation of nociceptors (e.g. primary hyperalgesia) is mediated via
sensitising substances released after tissue damage. These include inflammatory media-
tors, e.g. adenosine, adrenaline, bradykinin, prostaglandin or serotonin, as well as neu-
rotrophic substances such as the various nerve growth factors (12,13). Peripheral modu-
lation involves phosphorylation of the tetradotoxin resistant sensory neurone-specific
sodium ion channel (SNS/PN3), and possibly the type 1 vanilloid receptor VR1, altering
activation characteristics, increasing sodium current size with depolarisation, and lead-
ing to nociceptor hypersensitivity (14-16). Phosphorylation produces protein kinase A or
C activation by intracellular kinases activated via receptors coupled to G protein- or mem-
brane-bound tyrosine kinase (17-20). 
Centrally, i.e. at spinal and supraspinal levels, modulation (central sensitisation) is evoked
by primary afferent nociceptor input. Such input leads to facilitated excitatory synaptic
and depressed inhibitory functions, affects activated (homosynaptic modulation) as well
as adjacent (heterosynaptic modulation) synapses, and results in augmented responses
and expanded receptive fields to nociceptive and non-nociceptive inputs (21-26).
Homosynaptic modulation operates primarily via the AMPA receptor system and is
dependent upon NMDA receptor activation and either high intensity or high frequency
input, as seen in long-term potentiation of supraspinal (e.g. hippocampal) neurones
(5,27). As nociceptors only fire at low frequencies, physiological homosynaptic modula-
tion is likely to be limited to intense nociception. The mechanisms involved include
18
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Figure 4: Summary of mechanisms of peripheral modulation (from reference 4). Abbreviations: EP = prostaglandin E
receptor; BK = bradykinin;VR1 = vanilloid receptor; PKA = protein kinase A; PKC = protein kinase C; SNS/PN3 = tetrado-
toxin resistant sensory neurone-specific sodium ion channel.
enhanced AMPA (and kainate) channel conductance and cell-surface expression as well
as enhanced NMDA receptor function (5,27-29). In contrast, heterosynaptic modulation
is elicited by low frequency input, being elicited by anything longer than transient C-
fibre stimulation (30,31). It plays a major role at the spinal posterior horn, recruiting new
input sources (e.g. from A-delta fibres), expanding receptive field size as well as facilitat-
ing synapses not previously activated by conditioning stimuli (32-34). Here, presynaptic
release of neurotransmitters (NMDA) and neuromodulators (substance P, brain-derived
neurotrophic factor BDNF) alters spinal posterior horn signal transduction via effects on
postsynaptic ligand-gated ionophores (NMDA-R-glutamate), metabotropic receptors
(mGluR-glutamate, NK1-substance P) and tyrosine kinase receptors (TrkB-BDNF), with
important contributions from pre- and postsynaptically released prostaglandin E and
prostacyclin acting on IP receptors (35,36). NMDA, NK1 and mGluR receptor activation
plays a central and crucial role in the process of modulation and central sensitisation,
with two main mechanisms being described for this increase in cell gain. The first oper-
ates via suppression of Mg++ block of NMDA channels, the result of cumulative depolar-
isation with summing of slow synaptic potentials, as described above (37). The second
19
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Figure 5: Summary of mechanisms of central modulation (from reference 4). Abbreviations: Glu = glutamate; P2X =
ATP-gated purinergic receptor; NMDA = N-methyl D-aspartate; BDNF = brain-derived neurotrophic factor; NK1 = neu-
rokinin 1; mGluR = metabotrophic glutamate receptor; IP3 = inositol 1,4,5-trisphosphate; MAPK = mitogen-activated
protein kinase; PKC = protein kinase C; Src = a tyrosine kinase; TrkB = tyrosine receptor kinase B; VGCC = voltage-gated
calcium channel; GABA = gamma-amino-butyric acid; GLY = glycine.
mechanism results in enhanced NMDA ionophore gating, e.g. via phosphorylation
(35,36). This most likely occurs via several signalling cascades which increase intracellu-
lar Ca++ concentrations and activate calcium-dependent enzymes (protein kinase C,
calmodulin kinase), protein kinase A (via G-protein coupled receptors, e.g. NK1, EP,
mGluR) and/or tyrosine kinases (e.g. trkB receptor, itself a tyrosine kinase activating
other tyrosine kinases such as Src or protein kinase C) (35,36,38). These mechanisms have
also been demonstrated to be involved in excitatory amino acid receptor upregulation
(non-receptor protein tyrosine kinase Src for NMDA receptors) or channel insertion (pro-
tein kinase C for AMPA receptors) (38,39). Other mechanisms independent of the NMDA
receptor may, however, also play a role in central modulation, e.g. via altered expression
of AMPA receptors, which permits increased neuronal Ca++ influx and thus long-lasting
facilitation of synaptic transmission (28,29,40).
Two other aspects need to be considered regarding central modulation. First, it should be
remembered that central modulation also involves depression of inhibitory systems. At the
spinal level, e.g., activation of A-delta afferents can cause long-lasting depression of
inhibitory, largely GABAergic and glycinergic, primary afferent synapses (4,41). Again,
this effect is dependent upon NMDA receptor activation and subsequent rises in postsy-
naptic intracellular calcium concentrations. Second, supraspinal systems make a signifi-
cant contribution to development and maintenance of central sensitisation (42). Such
descending facilitatory systems frequently originate in the same brainstem regions as
those producing descending inhibition (e.g. the rostral ventromedial medulla RVM) (42).
It seems that low intensity electrical or chemical stimulation of these sites will tend to
facilitate spinal nociception (e.g. via activation of “on-cells”, mainly found in the nucle-
us raphe of the RVM), while high intensity electrical or chemical stimulation will result
in spinal inhibition (e.g. via activation of RVM “off-cells”) (43-46). However, the facilita-
tory and inhibitory systems operate via distinct anatomical spinal pathways (e.g. ventro-
lateral vs. dorsolateral funiculi) and receptor systems (e.g. serotoninergic and cholecys-
tokininergic vs. cholinergic and monoaminergic receptors) (42). Regarding facilitation
originating in the RVM, it is proposed that nociceptive input to the RVM via primary
afferents and then spinobulbal tracts (and possibly direct hepatic vagal afferents and the
nucleus tractus solitarius) activate RVM on-cells via mechanisms involving NMDA and
neurotensin receptors as well as nitric oxide (43,45,47-49). These on-cells then project
back to spinal posterior horn laminae I, II and V to produce facilitation of spinal noci-
ceptive transmission (50,51). The important role of supraspinal facilitation in central
modulation is supported by a number of studies demonstrating suppression of central
sensitisation due to inflammation or nerve damage by spinal cord transection or inacti-
vation of supraspinal sites (52-57).
20
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2.1.3. Chronic Excitatory Neuroplasticity: Modification
In peripheral modification, changes in target-derived growth factors in primary sensory
neurones or peripheral nociceptors play a major role. These signal molecules, which nor-
mally undergo retrograde axonal transport from the periphery (target) to the centre (cell
body), increase with inflammation and decrease with nerve (axon) damage due to loss of
contact with the target (58). The function of target-derived growth factors changes in the
course of development, being vital for neuronal survival early on, but then contributing
to neuronal phenotype maintenance in the adult phase (4,58). Alterations in target-
derived growth factor levels lead to significant changes in neuronal function via modified
expression of ionophores, neurotransmitters, synaptic neuromodulators and G protein-
linked receptors, as well as growth-associated and structural proteins (4,58). Another
mechanism involved in peripheral modulation is change in sensory neurone transcription
elicited via calcium influx through purely voltage-gated ionophores (36). 
Inflammation is associated with an increase in target-derived growth factors. This causes
upregulation of constitutive gene expression such as for SNS and VR1, making the
peripheral terminal more prone to sensitisation, e.g. via inflammatory mediators (59,60).
Such effects are supported by increased production of synaptic neuromodulators such as
substance P or BDNF (61-63). Inflammation also results in induction of novel genes. An
important example is the new expression of substance P and BDNF by A-delta fibres (and
even sometimes A-beta fibres), which acquisition of the neurochemical features of C-
fibres dramatically increases the ability of tactile stimulation of inflamed tissue to pro-
duce central sensitisation (36,64,65). In contrast, peripheral nerve injury results in a
decrease of target-derived growth factors, and thus reduced levels of substance P, SNS,
VR1 and CGRP. In addition, µ-opioid receptor expression is decreased, perhaps con-
tributing to decreased opioid sensitivity, and brain sodium channel III production is
increased, perhaps promoting increased ectopic neuronal activity (60,66-68). However, as
in inflammation, BDNF production is increased in peripheral nerve injury, and similar
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Figure 6: Summary of mechanisms of peripheral modification (from reference 4). Abbreviations: VR1 = vanilloid
receptor; SNS/PN3 = tetradotoxin resistant sensory neurone-specific sodium ion channel; BDNF = brain-derived neu-
rotrophic factor.
phenotype changes with expression of novel genes are observed, e.g. substance P and
BDNF expression in A-delta fibres, permitting these to induce central sensitisation
(69,70,71). Furthermore, nerve injury is associated with delayed sensory fibre loss, pref-
erential for C-fibres, as well as spinal rewiring through A-beta fibres sprouting to estab-
lish functional synaptic contacts with regions normally only supplied by C-fibre input
(i.e. superficial as opposed to deep posterior horn laminae) (72-75). The latter phenome-
non is highly abnormal, likely contributing to the frequently observed, refractory tactile
allodynia and other sensory pathologies seen in neuropathic pain syndromes.
Central modification (e.g. in posterior horn neurones), e.g. with inflammation or nerve
injury, involves further modified transcription, with alterations in transmitters/modula-
tors (dynorphin, enkephalin, GABA, COX2) and receptors (e.g. NK1, TrkB, GABA) subse-
quent to protein kinase cascade activation (e.g. mitogen-activated protein kinase, MAPK
or cAMP responsive element-binding protein, pCREB) (76-78). These changes are proba-
bly due to increased electrical activity resulting in greater calcium influx via voltage-
gated calcium channels (4). Again, inflammation is associated with increased expression
of receptors and associated substances, generally the same ones as in peripheral modifi-
cation, with similar but central effects producing increased central modulation (58).
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Figure 7: Summary of mechanisms of central modification (from reference 4). Abbreviations: Glu = glutamate; P2X =
ATP-gated purinergic receptor; NMDA = N-methyl D-aspartate; BDNF = brain-derived neurotrophic factor; COX2 =
cyclooxygenase 2; PGE2 = prostaglandin E2; NK1 = neurokinin 1; mGluR = metabotrophic glutamate receptor; IP3 =
inositol 1,4,5-trisphosphate; PKC = protein kinase C; TrkB = tyrosine receptor kinase B; VGCC = voltage-gated calcium
channel; EP = endoprostanoid; AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid; KAI = kainate;
GABA = gamma-amino-butyric acid; GLY = glycine.
Nerve damage results in decreased inhibition, e.g. via reductions in receptors and neuro-
transmitters as well as loss of inhibitory interneurones (79,80). The latter process is initi-
ated by neuronal injury discharge and ectopic activity, with subsequent cell death in the
superficial spinal posterior horn laminae, where inhibitory interneurones are mainly
localised (81,82).
2.2. Inhibitory Neuroplasticity
In intact organisms, nociceptive input elicits not only excitation but also inhibitory
responses. Such an interaction of excitatory and inhibitory systems is typical for other
sensory systems and for the central nervous system in general. Nociceptive processing is
no exception in this respect, and inhibitory responses form part of the complex modula-
tion which nociceptive signals undergo as they are transmitted from peripheral to central
in the nervous system (83). Inhibitory neuroplasticity can be divided into two main
types, spinal and supraspinal inhibition. 
2.2.1 Spinal Inhibitory Neuroplasticity
Spinal inhibition is mainly triggered by innocuous stimuli transmitted via large diameter
cutaneous afferents (e.g. A-beta fibres). This mechanism and its input is segmentally organ-
ised, being most effectively elicited by (non-noxious) mechanical stimulation in the
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Figure 8: DNIC demonstrated in the human model (from reference 105). Left: Setup of model and increasing inhibito-
ry effect of hotter conditioning stimulus. Right: Inhibitory effect of morphine on DNIC and its reversal by naloxone.
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inhibitory receptive fields surrounding the excitatory receptive fields (e.g. secondary
hyperalgesia) of convergent neurones (83,84). Propriospinal controls, possibly involving an
upper cervical relay, and triggered by noxious stimulation have also been described (83).
2.2.2. Supraspinal Inhibitory Neuroplasticity
Multiple systems have been described producing supraspinal nociceptive inhibition,
both tonic and phasic, and originating in the medulla and midbrain (83). As mentioned
before, the centres involved (e.g. rostral ventromedial medulla RVM or periaqueductal
grey PAG) are often the same ones as those implicated in supraspinal facilitation - albeit
involving different spinal pathways and receptor systems (85,86). The type of response
involved depends on stimulation characteristics (e.g. intense or weak), sensory test
modality (e.g. thermal or mechanical), pathophysiological condition of the organism (e.g.
inflammatory or neuropathic, acute or chronic) and neural pathways involved (87).
Supraspinal inhibition is considered to operate mainly via cholinergic or monoaminergic
neurotransmission and/or neuromodulation at the level of the posterior horn of the spinal
cord; particularly more rostrally, GABAergic interneuronal transmission is frequently
implicated as well (42,83). 
Tonic inhibitory descending controls on convergent spinal neurones have been demon-
strated to involve structures both in the rostral and caudal medulla (83,87,88).
Descending controls originating in the caudal medulla are mainly triggered directly by
nociceptive inputs, while activation of inhibition from the more rostral medulla (e.g. PAG
or RVM) may also involve environmental and contextual factors (83,87,88). The RVM con-
tains cells which control nociceptive transmission (50,51,89). Situated mainly in the
nucleus raphe magnus, and projecting onto spinal laminae I, II and V, activated “on-cells”
facilitate nociception and activated “off-cells” inhibit nociception, with the former being
activated indirectly via the PAG by µ-opioid agonists, and the latter directly inhibited by
opioids (90). Both these cells types are considered to be implicated in the development of
morphine tolerance, with “off-cells” being activated via excitatory amino-acid neuro-
transmission (51,90,91). The third class of cells present in the RVM, “neutral cells”, is
insensitive to opioids, and its role in nociception is unknown at present (90). This PAG-
RVM circuit has been shown to contribute to analgesia in humans, with descending inhi-
bition being activated not only by nociception, but also by PAG stimulation, acute stress
or the expectation of relief (89). Stress-induced analgesia has been described in least two
forms: “opioid” and “non-opioid” (e.g. mediated by NMDA-based mechanisms), with
more severe forms of stress being likely to stimulate the latter, and milder ones the for-
mer (93,94). 
Another well-described supraspinal inhibitory system is that of diffuse noxious inhibito-
ry controls (DNIC) (83,88,95,96). This phasic inhibition is exclusively triggered by noci-
ceptive, heterosegmental afferent A-delta and C-fibre input from parts of the body dis-
tant to the convergent spinal posterior horn neurones’ excitatory receptive fields. The
resulting powerful inhibition is selective for the wide dynamic range (WDR) spinal con-
vergent neurones and thus can affect both nociceptive and non-nociceptive processing.
Structures situated in the caudal medulla (e.g. subnucleus reticularis dorsalis) and sepa-
rate from those involved in the more tonic inhibitory controls described above are impli-
cated, with the afferent arm of the loop ascending in the ventrolateral, and the efferent
part in the dorsolateral spinal funiculi (83,88,95,96). More rostral lesions, such as affect-
ing the PAG, RVM (including nucleus raphe magnus), cuneiform nucleus, locus
coeruleus/subcoeruleus, gigantocellular and paragigantocellular nuclei, and the
parabrachial area, do not significantly affect DNIC (97,98). A major purpose of DNIC is
considered to be improvement of the signal-to-noise ratio between spinal neurone pools
activated nociceptively, and those not activated and thus remaining silent, thereby facil-
itating the extraction and interpretation of nociceptive information (97-100). There is evi-
dence that the acute inhibitory controls elicited by, e.g. inflammation, may decrease with
time as inflammation becomes chronic (101-103). Another interesting finding is that, in
contrast to other forms of descending inhibition, opioids in the lower dose range inter-
fere with DNIC, via mechanisms at least partially involving the PAG (98), but not direct-
ly involving the RVM (104). Thus in this context, supraspinally mediated (low-dose) opi-
oid analgesia would not result from reduced nociceptive inputs, but rather from interfer-
ences in the detection of nociception via lower nociceptive signal-to-noise ratios due to
reductions in DNIC (97,99,100).
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3. PRACTICE - MEASURING NOCICEPTIVE NEUROPLASTICITY 
IN THE CLINICAL CONTEXT
It may be considered self-evident that an understanding of the mechanisms involved in a
disease process involving pain and nociception is fundamental to its effective therapeu-
tic management (1). From the data presented in the previous chapter, nociceptive neuro-
plasticity is a real potential target for diagnostic measures permitting insight into the
pathological mechanisms underlying nociception, and could well provide the basis for
the shift from symptom-based to mechanism-based therapeutic approaches in pain med-
icine (2). A number of questions arise, however, when we start considering nociception
and neuroplasticity in the clinical context, i.e. monitoring neuroplasticity in the individ-
ual patient: 
1 How relevant is the question of nociceptive neuroplasticity to the clinical phenome-
non of pain?
2 For nociceptive neuroplasticity, can we extrapolate basic research data (e.g. animal
models) to the clinical situation?
3 Can we objectively measure nociceptive neuroplasticity in a clinical context?
3.1. Nociceptive Neuroplasticity vs. Pain in the Clinical Context
At present, our understanding of the consequences of nociception in the clinical context
is usually based upon the patient’s subjective pain experience, typically quantified via pain
intensity rating, measuring analgesic drug use, or possibly descriptive pain scoring via a
questionnaire (3). However, the use of subjective pain experience as a measure of noci-
ceptive neuroplasticity - as opposed to its direct, objective measure - can be expected to
be problematic due to the multifaceted and multifactorial nature of the pain experience
and its indirect and complex links to nervous system neuroplasticity. In animal models,
the connection between neuroplasticity and changes in behaviour following nociception
remains ill-defined. Moreover, the relevance of animal behaviour to the human pain expe-
rience is also unclear, further limiting the application of animal nociception research to the
clinical situation. In humans, the relationship between clinical pain measures and post-
nociceptive neuroplasticity is little investigated, with the research available suggesting
varying and generally weak correlations between the two (4-6).
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As described above, nociceptive input undergoes extensive processing before resulting in
the subjective experience of pain (figure 1,2). This pain experience includes both senso-
ry (e.g. pain intensity, pain location) and affective (e.g. unpleasantness, suffering) facets,
with the latter being further subdivided into primary (immediate implications, e.g.
unpleasantness) and secondary (future implications, e.g. suffering) aspects (7). Human
subjects can differentiate between the two facets if asked to, and the differential effects
of various analgesic drugs on these two facets of pain are well-described (8). Personality
traits have been demonstrated to have the least effect on the sensory facet of pain, and
the most on the affective facet, particularly its secondary aspects (9,10). The complex
path from nociceptive input to the pain experience involves both serial and parallel cen-
tral nervous system processing (8,11-14). From a number of studies, involving psy-
chophysical techniques as well as functional neuroimaging, we now know that affective
aspects of pain are processed in series with (i.e. downstream from) sensory aspects, with
parallel processing occurring for arousal and activation of both autonomous and somato-
motor nervous systems (15-19). Indeed, the major access of nociceptive spinal posterior
horn input to the anterior cingulate cortex, a major centre for integrating attentional and
evaluative (e.g. cognitive) factors into overall affective pain valency (and thus response
priorities), is indirect, serial and multisynaptic via a ventrally directed somatosensory-
limbic pathway (17-20). In contrast, nociceptive spinal posterior horn input has direct,
parallel access to lower brainstem and limbic structures mediating arousal and autonom-
ic and somatomotor activation (12-14). Thus it can be expected that the pain experience
- particularly its affective facets - will reflect nociceptive input less directly than arousal
Figure 1: Sensory processing linking nociception, arousal and the pain experience (from reference 7). The CNS struc-
tures likely to be involved are given in brackets, abbreviations: PAG = periaqueductal grey, PB = parabrachial nucleus
of the dorsolateral pons, VMpo = ventromedial part of the posterior nuclear complex, MDvc = ventrocaudal part of the
medial dorsal nucleus, VPL = ventroposterior lateral nucleus, ACC = anterior cingulate cortex, PCC = posterior cingu-
late cortex, HT = hypothalamus, S-1 and S-2 = first and second somatosensory cortical areas, PPC = posterior parietal
complex, SMA = supplementary motor area, AMYG = amygdala, PF = prefrontal cortex.
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and somatomotor/autonomic activation. This will be the more so, the more the pain meas-
ure used includes affective facets of the pain experience (e.g. analgesia use or “pain
relief” vs. specific pain intensity rating). Furthermore, there is evidence that intensity
coding of nociceptive input is well preserved with rostral progression in the central nerv-
ous system (16), thus even quite rostral nociceptive neuroplasticity should more directly
reflect the intensity of the original nociception than the subjective pain experience. 
Figure 2: CNS structures involved in processing the subjective pain experience (from reference 7). Abbreviations: PAG
= periaqueductal grey, PB = parabrachial nucleus of the dorsolateral pons, VMpo = ventromedial part of the posterior
nuclear complex, MDvc = ventrocaudal part of the medial dorsal nucleus, VPL = ventroposterior lateral nucleus, ACC =
anterior cingulate cortex, PCC = posterior cingulate cortex, HT = hypothalamus, S-1 and S-2 = first and second
somatosensory cortical areas, PPC = posterior parietal complex, SMA = supplementary motor area, AMYG = amygdala,
PF = prefrontal cortex.
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Taking all of these factors together, present evidence suggests that the relationship
between nociceptive neuroplasticity and the clinical pain experience is indirect, weak,
and in need of systematic investigation. Furthermore, nociceptive neuroplasticity is
potentially a better measure of “nociceptive load” (and the efficacy of its prevention and
therapy) than pain. If the outcomes - including pain - of disease processes involving noci-
ception are related to nociceptive load and its modulation, then nociceptive neuroplas-
ticity may prove to be a more useful and informative surrogate endpoint in this respect
than pain measures, and potentially interesting for both prognostic and therapeutic appli-
cation.
3.2. Extrapolation from Animal Models to the Clinical Situation
If data from animal models could reliably be extrapolated to the individual situation of
the patient, the need for monitoring nociceptive neuroplasticity in the clinical context
would be much smaller. From the account of nociceptive neuroplasticity presented above,
a number of inferences can be drawn of relevance to the question of extrapolation. It is
obvious that the change in central nervous system processing subsequent to nociception
is wide-ranging and complex, involving and integrating both excitatory and inhibitory
as well as peripheral, spinal and supraspinal systems. Thus, in view of the high degree of
integration and interaction of the systems involved in the response to nociception, obser-
vations on the reaction of isolated parts of the nervous system to nociception are unlike-
ly to permit accurate and comprehensive prediction of the reaction of the whole, intact
nervous system to nociception. Furthermore, the reaction of the nervous system, partic-
ularly the central nervous system, to nociception must be highly dependent on the ini-
tial state of the system, both internal and external, making details of the response very
specific to the model used. Of note is that this supposition includes the therapeutic con-
sequence that it will be more difficult to restore the activated system to its original state
than to prevent this state from occurring. Finally, the nociceptive neuroplasticity actual-
ly present will vary according to the timepoint after nociception at which it is observed
(i.e. acute vs. chronic neuroplasticity). 
These factors taken together suggest that it will be difficult to forecast the integral neu-
roplastic response of a given patient to specific nociception from data gathered in the ani-
mal experimental context (5). This is the consequence of prediction being based upon a
different, often non-intact (e.g. spinalised) species of animal, frequently investigated in a
different state of health (e.g. otherwise healthy, anaesthetised animal vs. awake human
with chronic autoimmune disease), often for a short time span, and many times involving
nociceptive stimuli unlike those seen in the clinical context (i.e. electrical C-fibre stimu-
lation vs. fractured bone). As an example of the problems involved, the debate about pre-
emptive analgesia and surgery conducted over the last decade or so has provided us with
a graphic illustration of the pitfalls involved in predicting clinical nociception outcomes
based on data about nociceptive neuroplasticity in animal models (4).
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3.3. Measuring Human Neuroplasticity in the Clinical Context
The desirable transfer from symptom- to mechanism-based pain and nociception man-
agement is predicated upon the availability of clinically practicable ways of objectively
assessing and measuring nociceptive neuroplasticity in patients. A variety of methods for
measuring nociceptive neuroplasticity are at present available in the experimental con-
text, involving either neuroimaging, neuroelectrophysiological, or psychophysical tech-
niques. The first two methods have provided much useful, detailed and innovative infor-
mation regarding nociceptive mechanisms, factors influencing them, and their therapeu-
tic modulation. However, neither method is at present practical for clinical monitoring
use in the sense of providing repeated measures of nociceptive neuroplasticity in multi-
ple patients at an affordable price and in a way that is acceptable to the patient.
3.3.1. Functional Neuroimaging Methods
Functional neuroimaging techniques represent the most recent and most sophisticated
addition to the armamentarium of methods for following the changes in nervous system
function with nociception. They involve making visible the metabolic changes (e.g. blood
flow) accompanying central nervous system function, and are either based on radioiso-
topic methods (e.g. positron emission tomography PET) or magnetic resonance techniques
(fMRI) (21,22). Quite a number of studies have appeared over the last years using these
techniques to elucidate central mechanisms involved in a variety of pain states. A notable
success in this context is the demonstration and elucidation of the cortical neuroplastic-
ity accompanying amputation (23). This is implicated in the pathogenesis of phantom
pain after amputation, and institution of various treatment strategies based on (demon-
strably) reducing this cortical reorganisation is proving successful in reducing phantom
pain. Another pain state in which neuroimaging has made significant contributions to
understanding the underlying pathophysiology is migraine headache (24). Neuroimaging
studies have provided the means to gain extensive and detailed insight into the alter-
ations of central nervous system function associated with nociception and pain, as well
into their therapeutic modulation. However, at present functional neuroimaging is expen-
sive, time-consuming and only performed in dedicated locations, thus making its routine
use in the day-to-day clinical context impractical (25). 
3.3.2. Neuroelectrophysiological Methods
Neuroelectrophysiological techniques involve the measurement of the electrical activity
accompanying nervous system activity (e.g. electroencephalogram EEG or electromyo-
gram EMG), and may be either evoked (a stimulus is presented and the resulting response
of the central nervous system quantified; e.g. evoked potentials, evoked reflexes) or pas-
sive (observing what happens to the EEG in a particular situation, e.g. event-related
potentials). Pain-evoked potentials (e.g. via laser stimulation), RIII-reflex determination
(an electrically evoked nociceptive reflex) and EEG arousal reaction (an event-related
potential) are classic illustrations of neuroelectrophysiological techniques used in the
investigation of pain and nociception (26-28). 
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Neuroelectrophysiological measures have proven particularly helpful in the investigation of
pain and nociception in the context of general anaesthesia, where psychophysical methods
(which require consciousness) are impossible to apply. In this context, both the EEG and
evoked potentials have been used to detect supraspinal excitation or inhibition following
nociceptive input (29,30), with the EEG giving a more holistic picture of the cortical reaction,
and evoked potentials looking more at specific pathways and structures. The application of
topographic (e.g. mapping, dipole source determination) and temporal (e.g. evoked reactions,
signal averaging) techniques has proven valuable when used to determine the pathways and
structures implicated in the processing of nociception and pain (29,31). However, the routine
clinical application of these techniques is made onerous by their large intra-individual vari-
ability in awake subjects and their time-consuming and technically demanding nature. Their
most promising clinical use at present is for nociception monitoring during anaesthesia (32).
In the context of investigating spinal nociceptive processing, electrophysiological tech-
niques specifically targeting spinal nociceptive mechanisms have proven to be of partic-
ular importance. Given that the study of spinal processing is difficult with psychophys-
ical or neuroimaging approaches, the development of methods such as nociceptive flex-
ion reflexes (e.g. the R-III reflex) (33) has proven invaluable. Unfortunately, as for
supraspinal electrophysiological techniques, the application of spinal electrophysiology
to routine clinical use is at present not practicable, again due to its time-consuming and
technically demanding nature.
3.3.3. Psychophysical Methods
Psychophysical techniques study the relationship between physical stimulation and
resulting sensation. They thus detect neuroplasticity via the changes produced in stimu-
lus-response curves, such as the left-ward shift resulting from hyperalgesia.
Psychophysical methods are suitable for everyday clinical use as the equipment is
portable and not overly complicated, and the protocols involved can be adapted to limit
the time necessary to perform them (34). Typical examples in pain research include the
determination of thresholds (e.g. pain tolerance threshold) to various stimuli (e.g. electric,
mechanical or thermal), and the rating by subjective measures (e.g. pain intensity visual
analogue scales) of stimuli of varying intensity (usually above threshold), e.g. in order to
obtain dose-response relationships (35). For formal, quantitative testing of somesthetic
function (quantitative sensory testing, QST), standardisation and validation of both test
stimuli and testing paradigms is of particular importance. Standardised and validated
testing protocols were first developed in the context of sensory testing for neurological
disease (e.g. diabetic neuropathy), starting over a decade ago (36,37). Since then the appli-
cation of such protocols has been extended to nociception and pain research by several
groups, resulting in a number of protocols for performing quantitative sensory testing in
the field of pain research (6,38,39).
37
3
Monitoring Nociceptive Neuroplasticity
Quantitative Sensory Testing: A Better Therapeutic Endpoint for Managing the Pain of Surgery?
For clinical application, a trade-off between accuracy (which lengthens protocols) and
practicability (which makes them less comprehensive) has to be made. The data collected
should, however, inform about the effects of stimulation modality (e.g. electrical, mechan-
ical, thermal), summation (e.g. temporal, spatial) and topography (e.g. generalised, seg-
mental). To date, quantitative sensory testing has been applied in many clinical experi-
mental contexts including various types of neuropathic pain, complex regional pain syn-
dromes, and soft-tissue/joint disorders such as fibromyalgia or osteoarthritis (36-40). In
the future, testing different types of structure (e.g. somatic vs. visceral, superficial vs.
deep) will assume increasing importance, although at present this is still very much sub-
ject to experimental development. 
Transcutaneous electrical stimulation remains a foundation of clinical QST in view of its emi-
nent controllability, ease of use, and extensive as well as long-standing record of validation
(41). Its advantages include a) the ability to provide well-defined single and summated stim-
uli, b) proven sensitivity to excitatory and inhibitory (e.g. DNIC) neuroplasticity, and c) the
potential to stimulate of a wide range of tissues (e.g. skin, muscle). Disadvantages include a)
the non-physiological nature of the stimulus, and b) the need to adapt existing methods to
include a topographical element.
Mechanical stimulation is well-established in practice and includes the use of graded fila-
ments (e.g. von Frey hairs) and pressure algometers (6,39,42). The facts that a) this is a phys-
iological stimulus with proven sensitivity to excitatory neuroplasticity, and b) the filaments
are eminently suited to sensory mapping, are clear advantages. However, disadvantages
include that a) filaments do not provide pain tolerance thresholds and must be used very
carefully to achieve precise, reproducible results, b) pressure algometers are not easily
applied everywhere (best over bony prominences), c) mechanical stimulation appears to be
less sensitive to inhibitory neuroplasticity than electrical stimulation in the post-surgical
context, and d) pressure thresholds are more influenced by gender than others (43).
Thermal sensory testing is at present achieved mainly by Peltier element or laser stimula-
tion and is a traditionally recognised method in pain research (44,45). Both methods have
achieved a high degree of sophistication and are frequently used in pain research. The
advantages of thermal testing are that it is a) an eminently controllable physiological stim-
ulus, and b) sensitive to excitatory neuroplasticity. The main disadvantage is that it rep-
resents a monomodal stimulus highly selective for certain peripheral nerve fibre subpop-
ulations, which might limit its application to the multimodal surgical context. 
Thus we have in quantitative sensory testing involving psychophysical methods a
defined, validated, practicable and affordable technique with the realistic potential of
being applicable to everyday clinical practice for the diagnosis and monitoring of noci-
ceptive neuroplasticity. The different stimulus modalities (i.e. electrical, mechanical, ther-
mal) may be at least partially complementary in the information they provide, with elec-
trical stimulation appearing to provide the most comprehensive coverage at present.
Further research is necessary to define the exact differential and comparative usefulness
of the various stimulus modalities either alone or in combination.
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4. STUDY GOALS - QUANTITATIVE SENSORY TESTING,
ANALGESIA AND NOCICEPTIVE NEUROPLASTICITY
Pain associated with surgery continues to be a major clinical challenge (1). Over 80% of
patients in a large British survey reported experiencing significant pain after surgery, and
in one third of these patients, such pain was present most or all of the time (2). An
American survey of pain and surgery found that postoperative pain was the primary con-
cern of patients preoperatively, and that three quarters went on to suffer significant post-
operative pain (3). Apart from the humanitarian obligation of treating postoperative pain,
adequate perioperative management of pain and nociception is now accepted to play an
important role in reducing postoperative morbidity, improving clinical outcomes and
speeding the patient’s recovery. A recent large meta-analysis of the intraoperative use of
neuraxial anaesthesia, which considerably attenuates intraoperative nociceptive input,
has demonstrated reduction of mortality by one-third, together with lower risk of deep
venous thrombosis, pulmonary embolism, blood transfusion, pneumonia, respiratory
depression, myocardial infarction and renal failure (4). Postoperative neuraxial analgesia
has also been demonstrated to be of benefit, particularly regarding pulmonary complica-
tions (5). Despite such insight into the importance of perioperative management of noci-
ception and pain, despite considerable advances in understanding nociception and pain
mechanisms, and despite improvements in the system for treating postoperative pain (e.g.
by introduction of acute pain services), progress in achieving significant advances in
perioperative nociception and pain management has been slow.
Management strategies for perioperative pain and nociception have so far been symptom-
based (6). Traditionally, postoperative analgesia has been managed by asking the patient
about his pain experience. However, the alterations in central nervous system processing
(neuroplasticity) associated with surgical nociception are increasingly recognised to play
an important role in acute postoperative pain (7). Nociceptive neuroplasticity is also con-
sidered to be implicated in pain chronification, and hence to be of relevance to long-term
pain outcomes after surgery (7). In addition, as discussed above, nociceptive neuroplas-
ticity may provide a link to other outcomes (e.g. complications) after surgery, particular-
ly via metabolic and immunological mechanisms. Thus an understanding of the neuro-
plasticity allied with surgery is likely to provide insight into the mechanisms underlying
postoperative pain and associated with surgical nociception, offering the basis for a shift
from symptom-based to mechanism-based management strategies for perioperative pain. 
The detection and diagnosis of surgical nociceptive neuroplasticity is still very much in
the early stages of development, with little systematic research having been performed in
this area to date. Several promising methods for the quantification of changes in sensory
processing are available - and reasonably well-validated - in the experimental arena.
However, the transfer of these methods to everyday clinical, surgical use is little investi-
gated and promises to be challenging. Clinical testing for surgical nociceptive neuroplas-
ticity demands both simplicity and rapidity in order to ensure its everyday feasibility.
At the same time, testing must not sacrifice a certain minimum of multimodality in order
to do justice to the complexity of surgical neuroplasticity. Taking into account these con-
siderations, it would appear to us that psychophysical methods (i.e. quantitative sensory
testing) may provide an attractive approach to the postoperative quantification of noci-
ceptive neuroplasticity (8). 
Against this background, the main, overall aim of the research presented here is thus to
provide the first basis for a change from symptom-based to mechanism-based manage-
ment of perioperative pain and nociception. Our plan was to achieve this by using quan-
titative sensory testing (QST) as a means of exposing the mechanisms underlying periop-
erative analgesia and pain. This approach has, to date, been rarely applied in the clinical
context, with a systematic investigation not having been published so far. Section III will
provide the introduction to this topic. It covers the feasibility of using QST to quantify
pharmacologically induced analgesia and antinociception in healthy persons without the
influence of surgery. In section IV we then go on to systematically explore the neuro-
plasticity resulting from surgical nociception using QST. Furthermore, we study the
influence of clinically important factors such as analgesia and preoperative pain on post-
operative surgical neuroplasticity.
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5. INTRODUCTION - QUANTITATIVE SENSORY TESTING AND 
ANALGESIA MEASUREMENT
The purpose of the studies presented in this section is to help us to understand and opti-
mise the performance of quantitative sensory testing (QST) in the human, clinical context
by applying it first to the investigation of analgesia before moving on to the more com-
plex issues of monitoring perioperative neuroplasticity. Antinociception and analgesia
are an essential part of the anaesthesiological management of surgical nociception and
pain. As for surgical nociceptive neuroplasticity, analgesia has generally been quantified
up till now in the clinical context by measures of the subjective pain exeprience.
Classically, this involves documenting the reduction in pain intensity due to a clinically
relevant painful condition induced by analgesic intervention. Again, QST offers the
opportunity of obtaining a more objective measure by quantifying the shift in stimulus-
effect curves caused by the analgesic intervention (e.g. hypoalgesia to a defined experi-
mental painful stimulus). Thus it seemed logical to us to investigate whether the antinoci-
ceptive and analgesic effects of drugs with accepted anaesthetic and analgesic properties
could practicably be measured using QST. In particular, we wished to study how such
drugs affect QST measures of themselves, before going on to use QST in the more com-
plicated context of studying surgical nociceptive neuroplasticity and it modulation.
Since the first QST publications a quarter of a century ago (1,2) many studies reporting
QST use have been published, the bulk of which involve testing in the context of neuro-
logical disease (3). The application of formal QST paradigms to pain medicine took place
more slowly, with the majority of publications over the last 20 years investigating chron-
ic pain syndromes. Sensory thresholds are the most frequently used QST parameter, but
pain report after a fixed, usually suprathreshold stimulus is also used (4). Pain threshold
testing to determine analgesic effects of drugs in humans has been practised for at least
as long as formal QST testing (5), with a large body of literature (some 250 articles) involv-
ing a variety of techniques having been published since. 
Quantifying analgesia by means of QST techniques such as threshold testing requires
attention to a variety of methodological issues. These include:
1 choice of appropriate stimulus modality (e.g. electrical vs. mechanical)
2 choice of stimulus characteristics (e.g. phasic vs. tonic stimuli, pain detection vs. tolerance)
3 choice of appropriate time-points for measures
4 choice of an appropriate testing paradigm. 
For systemic analgesia quantification, topographic considerations are of lesser impor-
tance, making the measure of thresholds at multiple anatomical sites unnecessary.
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5.1. Stimulus Modality
The choice of stimulus modality is determined by a number of considerations.
Mechanical thresholds (pressure pain thresholds) are more influenced by gender than
electrical or thermal thresholds (6), and may be less sensitive to direct pharmacological
analgesic effects (7). Thermal stimulation is very specific for thin-fibre nociceptive affer-
ents and is eminently controllable and well-validated both via laser and Peltier element
application (4,8). With mechanical as well as thermal stimulation it is, however, difficult
to produce the intensive and multimodal nociceptive stimuli necessary to model clinical-
ly typical nociceptive inputs without permanent tissue damage, and thus to achieve clin-
ical relevance in assessing analgesia. In contrast, electrical stimulation, while not a strict-
ly physiological stimulus, has been demonstrated to be able to produce clinically relevant
nociceptive input - including sensitisation - without permanent tissue damage (9).
Furthermore, the analgesic effects of analgesic drugs may be modality specific (7). Taking
these factors into account, we chose to initially investigate both thermal and electrical
stimulus modalities for our experimental analgesia studies. 
5.2. Stimulus Characteristics
The major consideration is to use a nociceptive stimulus which has predictive relevance
to the clinical situation. Thus phasic and pain tolerance thresholds have more predictive
strength than tonic and pain detection thresholds, as the former are more likely to achieve
an adequate load of nociceptive input and to stimulate the C-fibres necessary for clini-
cally relevant pain and its consequences (e.g. sensitisation) (10,11). In addition, it is
important to include the elements of temporal and spatial summation in the choice of the
stimulus, as modulation of summation is important for the clinical effectiveness of anal-
gesia (12,13). Repeated and longer-lasting (tonic) stimuli are thus more likely to predict
clinically relevant analgesia than single and short-lasting (phasic) ones. The studies dis-
cussed here investigate the effects of a variety of stimulus characteristics in an attempt to
understand their applicability to and predictiveness of clinical analgesia.
5.3. Timepoints Of Measures
The timepoints chosen for threshold determination should take into account pharmacolog-
ical factors, both pharmacodynamic and pharmacokinetic (10). Thus bolus investigations
need to include multiple measures, with a higher density at the beginning of the study to
include the time of peak concentration, while infusion studies should ideally be performed
in steady-state. The need for higher density of threshold measures will of course necessi-
tate the choice of a QST measure that is simple, repeatable and rapidly performed. It is also
important to consider the differences between plasma and effect site drug kinetics. We pres-
ent both a bolus and an infusion study design here as examples of how timepoints of meas-
ure might be appropriately chosen in the investigation of experimental analgesia.
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5.4. Testing Paradigm
QST results are based on psychophysical responses. They are thus highly sensitive to
methodological details and susceptible to a great variety of internal and external envi-
ronmental influences (3). Therefore due attention must be paid, via strict experimental
protocols, to such details in order to achieve acceptable reproducibility and validity of
the results (14). In particular, it is important to consider the following points: 
1 minimise learning and habituation effects, e.g. via familiarisation and training sessions
before any actual study measures are made, e.g. via pseudo-randomisation of stimulus
presentation (3,14-16)
2 standardise the environment within which measures are performed, e.g. via standard
instructions to subjects (3,14,15)
3 standardise sites of QST testing, e.g. use and mark same stimulation sites throughout
study (14,15)
4 use validated testing paradigms, including methods to test for non-co-operation of the
patient, e.g. null stimuli (17). 
A number of validated testing paradigms are now available (3,14,15), based either on the
method of limits (stimulus increases up to threshold, at which time a button is pressed,
necessitating consideration of reaction time), levels or staircases (fixed stimuli, increasing
or decreasing according to response), or forced choice (subject indicates which of two
time epoch contains the target stimulus) (3,14,15). 
For the studies presented here, we chose the method of limits, as this type of algorithm is
quick and simple to perform with good reliability and validity (14). For thermal testing we
used a commercially available computer-controlled system with Peltier thermode, using a
well-validated algorithm, and incorporating the desirable design details listed above (15).
Electrical testing was performed manually using a standard nerve stimulator and tetanic
stimulation via self-adhesive ECG electrodes remaining in situ for the duration of the
study, again using a method of limits and incorporating the above design details.
The overall purpose of the studies presented here is as an introduction to the practical
use of QST in the context of pain. In particular we consider it important to first under-
stand the effects of analgesic and antinociceptive drugs by themselves on QST before
going on to study the effects of - and interactions with - surgery. Taking into account the
methodological issues detailed above, a major aim was to investigate the practicability and
performance of QST when used in the clinical context to study antinociceptive proper-
ties of anaesthetic or analgesic drugs. Detailed questions to be addressed by this research
included the following:
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1 When anaesthetics are used for sedation, do they also modulate nocicep-
tion, and if so, is this modulation affected by dosage and agent chosen?
2 How do different stimuli perform in demonstrating antinociception by an
opioid analgesic, and how do such different measures of analgesic effect
relate with plasma pharmacokinetics of the agent?
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8. SUMMARY - USING QUANTITATIVE SENSORY TESTING FOR 
QUANTIFYING ANALGESIA
The studies presented here (1,2) confirm the feasibility of quantifying drug-induced
antinociception and analgesia in human subjects using QST. This is in agreement with the
literature already available on this topic. Both thermal and electrical pain threshold test-
ing appear to be suited to this task, and it seems possible to adapt the paradigms to inves-
tigations under bolus as well as infusion conditions. We were able to teach the paradigms
used to naive subjects within about 15 minutes, and the procedure was well-accepted by
those taking part in the studies. The tests proved stable and reproducible over the study
periods (maximum variability of ca. 20% between measures), suggesting that these proce-
dures might be used to investigate routine clinical surgical patients with only minimal sim-
plification and adaptation. Thus the use of these QST paradigms for simpler experimental
analgesia studies in humans provided us not only with specific data on the antinocicep-
tive characteristics of the drugs studied, but also with valuable experience and insight for
their subsequent utilisation in the more complex context of clinical surgery.
8.1. QST and Sedation by Anaesthetic Drugs
Our study involved the use of an infusion of two frequently-used intravenous anaesthetic
drugs, thiopental and propofol, to sedate patients before surgery. Nociceptive processing
was studied by QST using thermal stimulation via a Peltier element. Two approximately
stable and hypnotically equipotent plasma levels were compared, corresponding to typical
light and moderate sedation. The rationale for studying nociceptive processing in this con-
text is that such sedation has often been accused in the literature of causing hyperalgesia
(i.e. increased sensitivity to pain), which would of course be undesirable for surgery.
Our prime finding is that neither light nor moderate infusion sedation was associated
with hyperalgesia for both propofol and thiopental. In fact, moderate sedation with
thiopental produced statistically and clinically significant depression of pain processing
by almost 20%. The difference between anaesthetic and analgesic drugs is clearly illus-
trated by the relationship between sedation (as measured by reaction time) and antinoci-
ception (as measured by threshold depression): for thiopental (moderate sedation), reac-
tion time increased by 94% for a decrease in threshold of 19%, for alfentanil (30µg/kg
i.m.) reaction time increases by 10% for decrease in threshold of 116%. Despite expecta-
tions that propofol would prove to have a better analgesic potency for a given hypnotic
potency in comparison to thiopental, this proved not to be the case in this study. Of inter-
est was also the fact that, for both anaesthetics, measures of antinociceptive potency
increased more slowly than measures of hypnotic potency with increasing dosage.
Thus this first study using QST during infusion sedation by intravenous anaesthetics not
only demonstrated that its use was practicable in this context, but also provided valuable
insight into the drugs’ antinociceptive properties and their relationships to hypnotic
potency at differing doses. In particular, we were able to demonstrate that dose-response
relationships differ between different anaesthetic drugs, not only for antinociception/
sedation relationships but also for the individual endpoints of sedation and antinocicep-
tion, as also suggested by other studies (3,4). 
8.2. QST Variables and Opioid Analgesia
The background to this study was the inability of certain authors to formally demonstrate
analgesic properties for morphine-6-glucuronide in the experimental context. In our
view, the studies unable to demonstrate morphine-6-glucuronide analgesia chose QST
variables inappropriate for quantifying opioid analgesia, using phasic, subthreshold stim-
ulation and too unspecific pain effect measures (e.g. pain-evoked cerebral late potentials).
We also wished to document plasma concentration-analgesia relationships for intra-
venous application and investigate if oral application could be effective.
The prime result of our study is to demonstrate that opioid analgesia, in particular mor-
phine-6-glucuronide analgesia, can be reliably quantified over time by QST using tonic,
suprathreshold stimulation and repeated visual analogue scaling. In this context, electri-
cal stimulation - despite its “non-physiological” nature - proved more sensitive than ther-
mal (cold) stimulation using ice-water bucket immersion. There was a time lag of about 45
minutes between peak plasma concentration and peak biophase effect (as measured by
reduction in evoked pain VAS), suggesting slow penetration into the analgesic central
biophase from the circulation. The oral application of 10 and 20 mg morphine-6-glu-
curonide proved ineffective, resulting in neither measurable plasma levels nor alterations
in evoked pain VAS. It should be noted in this context that subjects found suprathresh-
old stimulation more disagreeable than threshold determination.
The present study highlights the importance of choosing appropriate QST paradigms and
stimuli if analgesic effects are to be consistently demonstrated and followed. In the con-
text of opioids, this means giving preference to tonic and suprathreshold stimuli. It is of
practical and clinical interest that the pharmacodynamics of opioid analgesia can reliably
be quantified and followed using the QST paradigms detailed here, and that the pharma-
codynamic time course can lag substantially behind the pharmacokinetic time course.
8.3. Implications for QST and Surgical Neuroplasticity 
Our experience from the studies discussed above led us to make a number of modifica-
tions for the surgical neuroplasticity QST paradigms. The major changes were that we 1)
preferred threshold determinations to methods involving the use of pain report to fixed
suprathreshold stimuli, as the former were more acceptable to subjects and were less
subject to variability, 2) concentrated on tonic/pain tolerance thresholds, as these
appeared more sensitive to changes than phasic/pain detection thresholds, and 3) decid-
ed not to use the ice-water immersion test as it was time-consuming, considered unpleas-
ant by the subjects, and less sensitive than electrical skin stimulation to nociceptive
modulation. From the pilot tests involved in these studies, we also learnt the importance
of adequate time spacing of the tests in order to avoid sensitisation and interference
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between measures. While we were of the impression that thermal testing QST paradigms
were more onerous to perform than the electrical ones, the difference was not sufficient-
ly large for us to completely abandon thermal testing, particularly the computer-con-
trolled, well-designed and validated testing paradigm in conjunction with electronic data
collection used in the first study (5,6).
Taking all of these results together, we suggest that QST, in particular thermal or electric
threshold testing, showed potential for the investigation of nociceptive processing mod-
ulation by drugs of known antinociceptive potency in humans, and commonly used in
the anaesthetic and surgical environment. Thus these studies prepared the ground for
investigating such QST paradigms in the context of perioperative alterations of nocicep-
tive processing (i.e. surgical neuroplasticity).
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9. INTRODUCTION - SYSTEMATIC INVESTIGATION OF SURGICAL 
NEUROPLASTICITY BY QUANTITATIVE SENSORY TESTING 
First attempts to use formal quantitative sensory testing (QST) to investigate neuroplastic
changes after human surgery began about a decade ago. A number of studies have been
published since then (1-10), with the majority involving the use of mechanical thresholds
(1-6,8,10), a couple applying electrical stimulation in combination with other electro-
physiological measures (7,9), and one study utilising thermal stimulation via a Peltier
thermode (10). To date, only two of these studies have studied post-surgical neuroplas-
ticity in a more detailed fashion by including both a longer time course (i.e. repeated
measurements over 7-8 days postoperatively) and investigation of the anatomical distri-
bution of sensory changes (i.e. primary versus secondary hyperalgesia vs. distant sites)
(1,2). The other studies cited generally embrace a time course of maximally 48 hours, and
often only comprise one or two measures in space and time. 
In the studies involving mechanical stimulation, pressure pain thresholds (1,3-6,8) tend
to be used more often than von Frey monofilaments (2-4,10). This is because, with regard
to nociception, von Frey hairs produce minor, punctate stimulation at best involving A-
delta fibres, whereas pressure algometry can be used to determine both pain detection (A-
delta fibre) and pain tolerance (C-fibre) thresholds. Most of the studies using mechanical
stimulation have determined thresholds at predetermined sites, but one study has intro-
duced the alternative technique of using von Frey hairs to map the area of punctate
hyperalgesia surrounding the site of surgery (i.e. secondary hyperalgesia due to central
sensitisation) and to assess wind-up pain due to temporal summation of stimuli (2). 
Pressure algometry has been most frequently used to quantify primary hyperalgesia
(wound tenderness) by measuring directly on the surgical incision (1,3-6,8). Taken
together, the studies cited show decreased pressure pain detection thresholds at the sur-
gical site up to 96 hours postoperatively (1), with one study even reporting the persist-
ence of primary hyperalgesia 3 months postoperatively (3). The degree of threshold
reduction appears to correlate with the total PCA morphine consumption at 24 hours
postoperatively (3). Primary hyperalgesia is unaffected (dextromethorphan (3), tenoxicam
(5)) or only very weakly affected (morphine (8)) by perioperative analgesia. One study
also looked at secondary mechanical hyperalgesia, which tends to decrease with distance
from the wound, and whose time course parallels that of the primary hyperalgesia pres-
ent up to 4 days postoperatively (1). The same study found no threshold changes distant
to the site of surgery (1), suggesting that mechanical thresholds may be relatively insen-
sitive to inhibitory neuroplasticity, in keeping with other evidence (11,12).
For the reasons discussed above, the use of von Frey hairs for threshold determination
in the context of surgical nociception has not proven very successful (4,11). They have,
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nevertheless, proven useful for mapping as well as for detecting the mechanical hyperal-
gesia and allodynia surrounding surgical incision (2,3). Using von Frey hairs in this way,
it has been shown that the pre- and intraoperative use of a low-dose ketamine infusion
significantly reduces the area of secondary hyperalgesia surrounding surgical incision vs.
placebo, as well as reducing allodynia in this area (2). This effect lasted for up to seven
days postoperatively, without a ketamine effect on primary hyperalgesia. Another such
study used von Frey hairs to measure postoperative primary wound hyperalgesia, with
the result that dextromethorphan - also an NMDA receptor antagonist - given preopera-
tively was again unable to reduce primary hyperalgesia compared to placebo (3).
Two early studies have used electrical skin stimulation together with electrophysiological
measures to quantify post-surgical neuroplasticity once at a single site 2-3 days postoper-
atively (7,9). The earlier one discovered evidence of inhibitory neuroplasticity compared
to subjects not having undergone surgery via raised sensation thresholds and decreased
somatosensory evoked potential amplitudes at a site distant to surgery (9). These results
would tend to support other evidence that dermatomal electrical stimulation is sensitive to
inhibitory neuroplasticity. Using direct electrical stimulation of the sural nerve, another
investigation found lowered pain detection thresholds after surgery compared to non-
operated volunteers, accompanied by a trend to decreased nociceptive flexion reflex (R-III
reflex) thresholds (9). Thus direct electrical nerve stimulation appears to be much less sen-
sitive to inhibitory controls, reflecting spinal central sensitisation more directly.
Thermal thresholds are considered to be particularly selective for the thin nerve fibres
(A-delta, C) relevant to nociceptive input (13). At present we have found only one study
using thermal thresholds in the surgical context (10). This study reveals the presence of
primary and secondary thermal hyperalgesia around the site of surgery up to six hours
postoperatively. Both primary and secondary early postoperative thermal hyperalgesia
are absent in patients given dextromethorphan preoperatively, with von Frey hair testing
being unable to detect a difference in mechanical hyperalgesia between the drug groups. 
Most of the studies quoted in the present discussion have not been able to demonstrate a
tight relationship between clinical measures of pain (e.g. pain scores, analgesic consump-
tion) and measures of surgical neuroplasticity (e.g. quantitative sensory testing). If there
is a relationship between pain and neuroplasticity, primary hyperalgesia (which is of
peripheral origin) would appear to have the strongest effect, with this effect being max-
imal during the first postoperative hours. Two studies suggest that primary hyperalgesia
has a formal, weak to moderate relationship with postoperative pain scores at rest or dur-
ing coughing (1) or with postoperative patient controlled morphine consumption (3). As
mentioned before, it should be noted that primary hyperalgesia has been shown to be
quite resistant to various forms of perioperative analgesia (3-5,8).
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Based on the articles above, we would summarise what is known about surgical neuro-
plasticity as follows: 
1 Primary hyperalgesia of the surgical incision (which is of peripheral origin) to mechan-
ical and thermal stimuli is better investigated and can be demonstrated up to 3 months
postoperatively. More studied than secondary hyperalgesia of central origin, it appears
to have a weak to moderate relationship to clinical pain measures, but is generally
quite resistant to (systemic) perioperative analgesic measures. 
2 Secondary hyperalgesia next to surgical incision (which is of central origin) can be
demonstrated postoperatively for mechanical (up to 96 hours) and thermal stimuli (up to
6 hours). Secondary mechanical hyperalgesia area size and degree of allodynia are signif-
icantly reduced by NMDA blockade with ketamine (2), while dextromethorphan reduces
thermal secondary hyperalgesia - but apparently not mechanical hyperalgesia (10). 
3 Distant to the site of surgery, postoperative sensory testing involving electrical stimu-
lation suggests the presence of central inhibitory mechanisms in the presence of cen-
tral spinal excitatory neuroplasticity at single times and sites (7,9).
From the above summary, the need for the systematic application of quantitative sensory
testing (QST) to investigate human post-surgical neuroplasticity in an integrated fashion
is evident. In particular, the central nervous system (CNS) plasticity accompanying sur-
gery remains largely unstudied, particularly regarding:
1 the feasibility of using QST to monitor surgical neuroplasticity in the everyday clini-
cal context
2 the detailed nature and time course of the neuroplastic response
3 the modulating effect of typical clinical factors on such neuroplasticity
4 the relationship between surgical neuroplasticity and clinical pain measures. 
Regarding the nature of the alterations in CNS sensory processing after surgery, we need
to address the details of excitatory vs. inhibitory neuroplastic reactions and the differen-
tial contributions of supraspinal vs. spinal mechanisms to these responses. The typical
clinical modulating factors which would benefit from study include both intrinsic (e.g.
preoperative pain) and extrinsic factors (e.g. perioperative analgesic management). 
The scheme for our clinical QST paradigms for surgical neuroplasticity was designed to
answer the questions discussed above and based upon experiences with analgesia quan-
tification (cf. section III). It takes the following criteria into account: 
1 simplicity (i.e. needing only minimal patient training, ca. 15 minutes)
2 rapidity (testing can be completed in ca. 15 minutes)
3 reproducibility (less than 20% interindividual variability)
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4 validation in published literature
5 multimodal testing (sensation, pain detection, pain tolerance)
6 multiple sites (sites close to and far from surgery). 
In the first phase of our investigations, we used thermal stimulation for QST due to its
nociceptive specificity and the availability of a well-validated testing device (14).
However, its use proved to be onerous in everyday practice, and we thus, in the second
phase, went on to test a paradigm based on thresholds to electrical skin stimulation. To
implement this paradigm we used a relatively simple device, which proved well-suited to
clinical employ.
The major aim of the study series presented here is to initiate systematic study of the neu-
roplasticity following surgical nociception. We are specifically interested in the feasibili-
ty and practicability of using QST for this purpose in the clinical environment.
Specifically, the aim of the study series presented here was to address, using QST, the fol-
lowing questions about human post-surgical central neuroplasticity:
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1 What is the nature and time course of post-surgical neuroplasticity?
2 How do a) analgesia and b) preoperative pain affect postoperative 
neuroplasticity?
3 What is the relationship between postoperative neuroplasticity and clinical
pain measures?
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ABSTRACT
Alterations in central sensory processing after nociception are complex and potentially a
significant factor in postoperative pain. We investigated the course of these alterations
after human surgery and how preoperative pain or analgesia affect them using quantita-
tive sensory testing, and compared them with clinical pain measures.
Patients with “minor” (VAS<3) or “major” (VAS≥3) pain before back surgery received
placebo, fentanyl or ketorolac (n=15/group) before isoflurane-nitrous oxide anaesthesia.
15. ARTICLE – PAIN, ANALGESIA AND POSTOPERATIVE
NEUROPLASTICITY
(Wilder-Smith OH, Tassonyi E, Crul BJP, Arendt-Nielsen L. Neuroplasticity after human surgery: Effects of
preoperative pain and analgesic management. Pain 2002; submitted)
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Preoperatively to 5 days postoperatively, we measured absolute and relative (normalisa-
tion to arm) thresholds to electrical skin stimulation at incision site, arm and leg, and pain
scores and morphine PCA consumption (24 hours postoperatively).
Absolute thresholds increased maximally 4 hours, and decreased maximally 5 days after
surgery (+42%; -49%; P<0.00005 vs. preoperatively). Increases were largest with fen-
tanyl (P<0.003), and differences between maximum and minimum values greatest with
major preoperative pain (P=0.03). Placebo patients with minor preoperative pain showed
threshold decreases postoperatively (relative: 1h - 5d; absolute: 24h - 5d); major preoper-
ative pain and fentanyl inhibited these. With ketorolac, absolute thresholds decreased
(24h - 5d) despite prevention of relative threshold reductions. Patients with major preop-
erative pain had less early leg pain, and used more morphine in total with ketorolac than
fentanyl (+134%, P<0.05). 
Patients with minor preoperative pain exhibit spinal and supraspinal excitation after sur-
gery under non-analgesic anaesthesia. Major preoperative pain and fentanyl inhibits such
changes. Ketorolac depresses spinal facilitation, but not late generalised hyperalgesia.
Postoperative sensory change is only partially expressed in clinical pain measures, sug-
gesting the usefulness of including quantitative sensory testing in future research.
Key Words
Pain: preoperative, postoperative, clinical, measurement
Quantitative sensory testing: transcutaneous electrical thresholds
Surgery: human, nociception, analgesia
Analgesics: fentanyl, ketorolac
1. INTRODUCTION
Acute and chronic nociception alter peripheral and central nervous system function (Raja
et al., 1988; Coderre et al., 1993). Animal studies have shown post-nociceptive changes in
central nervous system processing to be complex, varying according to time after noci-
ception, showing both inhibitory and excitatory patterns, and affecting spinal as well as
supraspinal structures (Coderre et al., 1993; Richmond et al., 1993; Jayaram et al., 1995;
Woolf and Salter, 2000). Altered central sensory processing due to nociception is consid-
ered to play an important role in the aetiology of pain after surgery in humans, and has
been postulated to be a potentially significant factor in determining acute - and perhaps
chronic - postoperative pain outcomes (Coderre et al., 1993; Woolf and Chong, 1993;
Woolf and Salter, 2000).
Extrapolation from animal data in this context is fraught with difficulty, as demonstrat-
ed by the pre-emptive analgesia debate, making the collection of actual human data nec-
essary (Wall, 1988; Kehlet, 1994; McQuay 1995; Urban and Gebhart, 1999; Wilder-Smith,
2000). However, human data as to the course and nature of altered central sensory pro-
cessing after surgery remain sparse. Furthermore, the relationship between objective
measures of altered central processing (e.g. psychophysical, electrophysiological meas-
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ures) and the inevitably subjective measures of pain experience (e.g. pain scores, analge-
sia use) after surgery is poorly understood. Finally, the effects of clinically typical and rel-
evant factors such as preoperative pain and/or analgesic management on postoperative
central sensory processing are largely uninvestigated.
Thus the first aim of the present clinical study, which bases upon and expands earlier
research (Wilder-Smith et al., 1996), is to investigate the time course of changes in
supraspinal and spinal central nervous system sensory processing up to 5 days after sur-
gery, as measured by quantitative sensory testing (QST) using thresholds to cutaneous
electric stimulation. A second goal is to study the effects on these postoperative process-
ing alterations of two common, clinically relevant factors, acute preoperative pain and
preoperative analgesia (i.e. fentanyl, an opioid, and ketorolac, an NSAID). A final purpose
of the study is to permit comparison between postoperative QST alterations and postop-
erative pain, as measured by clinical pain measures such as scores and analgesia con-
sumption.
2. MATERIALS AND METHODS
2.1. Study design and patients
Using a prospective, randomised, placebo-controlled and double-blinded design and
after institutional review board approval we studied 45 ASA 1 and 2 patients scheduled
to undergo elective surgery for intervertebral disc herniation. The surgical procedure
(fenestration, removal of disc fragments) was standardised and the same for all patients.
Patients were recruited the afternoon before surgery and gave written informed consent.
A detailed history and physical examination was performed. To recruit a homogeneous
group in whom pain - as opposed to neurological deficit - was the main symptom over
time, patients conformed to the following criteria: 1) significant pain over the last month
(score greater than 5, in the lower back, for more than three quarters of the time for at
least one month, accompanied by typical sciatic pain radiating into the leg), 2) significant
impairment of everyday activities due to this pain (for more than three quarters of the
time, for at least one month), and 3) significant and typical findings on physical exami-
nation (local lower back pain/tenderness, muscle stiffness/spasm, reduced mobility; pos-
itive Lasegue’s sign on at least one side). An additional indication for surgery was identi-
fiable anatomical intervertebral disc abnormality on neuroimaging. Exclusion criteria
included significant focal neurological motor deficit, peripheral neuropathy and diseases
predisposing to peripheral neuropathy such as diabetes mellitus or major alcohol abuse.
Bed rest and a standard anti-inflammatory scheme of 3x100mg of diclofenac p.o. daily
were started in all patients 3 days before surgery. Patients were thus under this regime at
the time of inclusion into the study, with some patients being rendered pain-free some of
the time by this course of treatment.
2.2. Patient groups
Patients received no premedication on the morning of surgery. On entering the operating
theatre, they were randomised into three drug groups by computer-generated randomi-
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sation table (n = 15 per group). Patients received a blinded short infusion of either 100
ml 0.9% NaCl (placebo group), 3 µg.kg-1 fentanyl in 100 ml 0.9% NaCl (fentanyl group),
or 30 mg ketorolac in 100 ml 0.9% NaCl (ketorolac group). This infusion was prepared by
a nurse otherwise not involved in the study to assure blinding. 
Before insertion of intravenous access, patients were asked about the presence and inten-
sity of pain due to the back (verbal pain intensity rating score: 0 = no pain; 10 = worst
imaginable pain). Based on this answer, patients were classified as having “minor”
(VAS<3) or “major” (VAS≥3) preoperative pain (preoperative pain status).
2.3. Threshold determination
Next, taking care not to stimulate major nerves directly, an observer blinded to the
patient’s pain status determined thresholds to transcutaneous constant current electric
stimulation (Digistim, Biometer A/S, Copenhagen, Denmark; tetanic stimulation at 100Hz,
0.2 ms square wave pulses, ramping rate ca. 0.1mA/s, applied via self-adhesive electrodes
3 cm apart). Thresholds were determined for sensation, pain detection and pain tolerance
(electric current just felt; just becoming painful; and just becoming intolerably painful;
respectively). They were measured at leg, (proposed) surgical incision and arm sites (L5-
S1 dermatome: point of maximum leg pain; T12-L1 dermatome: 5 cm from midline inci-
sion, contralateral and ipsilateral to the side of the nerve root involved; and C8-T1 der-
matome, contralateral to the nerve root involved; respectively). Thresholds were quanti-
fied consecutively in a run in an identical fashion and at identical sites in all patients. The
average of three runs separated by five minutes was used for analysis. If two threshold
values differed by more than 20% between runs, testing was repeated until stable.
Absolute, unmodified threshold values were used to evaluate generalised changes in cen-
tral sensory processing due to supraspinal but also spinal effects. To assess segmental,
spinal threshold changes we (mathematically) removed generalised effects by normalisa-
tion to a site distant from surgery (i.e. the arm site). Thus relative thresholds were calcu-
lated by dividing the threshold value at the site in question by the corresponding value
at the arm.
2.4. Anaesthesia and analgesia
Venous access was established and the patient received the blinded short infusion.
Approximately ten minutes later, anaesthesia was induced with thiopental 5 mg.kg-1 fol-
lowed by vecuronium 0.1 mg.kg-1. After tracheal intubation, isoflurane and nitrous oxide
in oxygen were used to maintain anaesthesia as necessary. No other drugs were used for
anaesthesia which always lasted less than one hour in total. Morphine patient-controlled
analgesia (PCA) was started in the post-anaesthesia care unit and continued until 24 hours
postoperatively (loading bolus: 60 µg.kg-1, demand bolus: 25 µg.kg-1, lock-out time: 8
minutes). For the period of morphine PCA, patients did not receive any other analgesics.
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During the first two hours’ stay in the post-anaesthesia care unit, a background infusion
of morphine 15 µg.kg-1.h-1 was used. This was discontinued on transfer to the ward, and
the lock-out interval increased to 15 minutes. After 24 hours, analgesia was continued to
day 5 by oral diclofenac at 3X100 mg p.o. only.
2.5. Times of measures
At 1, 2, 4, 6, and 24 hours and 5 days after extubation, thresholds, pain verbal intensity
rating scores in leg and back, observer sedation rating scores (5 = wide awake, 1 =
unrousable), and cumulative morphine consumption (except day 5) were measured as
described above. 
2.6. Statistical analysis
Based on previous results (5) the present study was predicted to have the ability to iden-
tify threshold changes of 20% for a group size of n=12 (alpha=5%; beta=20%; two-
tailed testing). Statistical analysis was performed using the software package Statistica for
Windows (release 4.5, Statsoft Inc., 2325 East 13th Street, Tulsa OK 74104, USA). Patient
group demographic data were compared using ANOVA or Kruskal-Wallis ANOVA-testing
as appropriate. Baseline absolute and relative thresholds were compared using 4-way
ANOVA (factors: drug group, measurement site, threshold type, preoperative pain status)
with post hoc Tukey Honest Significant Difference testing. Changes in group absolute and
relative thresholds were analysed using repeated measures 5-way ANCOVA (co-variant:
preoperative control thresholds; factors: drug group, measurement site, threshold type,
preoperative pain status, time) and post hoc Tukey testing. Pain and drug group differ-
ences in morphine consumption were tested for using 3-way repeated measures ANOVA
(factors: drug group, preoperative pain status, time) with post hoc Tukey testing. Pain
verbal intensity rating scores and observer sedation scores were compared between
groups using Kruskal-Wallis ANOVA, with Bonferroni-corrected post hoc Mann-Whitney
U testing as necessary. For all statistical analysis, significance was assumed for P<0.05,
correlations for R>0.6 were considered significant.
3. RESULTS
3.1. Patient characteristics
Patient demographics were similar in the three drug groups (placebo: age = 48±13 years,
weight = 74±13 kg, height = 172±10 cm, male:female = 9:4, no pain:pain = 10:3; fen-
tanyl: age = 41±11 years, weight = 74±15 kg, height = 174±8 cm, male:female = 12:3,
no pain:pain = 11:4; ketorolac: age = 45±12 years, weight = 72±11 kg, height = 170±6
cm, male:female = 10:3, no pain:pain = 10:3). Two placebo and two ketorolac group
patients had incomplete pain data and were excluded from analysis. 
3.2. Generalised sensory change: absolute threshold values
3.2.1. Baseline values
Baseline preoperative absolute threshold values did not differ according to drug group,
site of threshold testing or preoperative pain status. As covariant, preoperative thresh-
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olds were significantly and inversely related to threshold changes 24 hours and 5 days
after surgery (pooled within-groups correlations of -0.73 and -0.82, respectively). As to
be expected, baseline thresholds differed according to the type of threshold tested. 
3.2.2. Overall factor effects
Overall postoperative change in absolute thresholds was highly significantly affected by
the single factors drug group, type of threshold tested, preoperative pain status, and time
(Table 1). Post hoc testing revealed thresholds to be most increased in the fentanyl group
a. absolute thresholds 
factor(s) significance 
drug group P=0.0005 
test type P<0.000001
preoperative pain status P=0.03
time P<0.000001
drug group x preoperative pain status P=0.001
drug group x time P<0.000001
test type x time P<0.000001 
drug group x preoperative pain status x time P=0.00006 
b. relative thresholds
factor(s) significance
test type P=0.00002
time P=0.02
test type x time P=0.0003
preoperative pain status x time P=0.01
drug group x test type x time P=0.006
drug group x preoperative pain status x time P=0.0008
Table 1: Factors significantly affecting thresholds
Single and combined factors with significant effects on absolute and relative (i.e. normalised by division by arm thresh-
old values) postoperative thresholds (ANCOVA).
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(+41% vs. preoperative baseline; placebo: +29%; ketorolac +28%; P<0.003 vs. fen-
tanyl), and the difference between maximum and minimum values to be greatest with
minor preoperative pain (P=0.03 for minor vs. major preoperative pain). Absolute thresh-
olds reached their maximum 4 hours (+42%) and their minimum 5 days postoperatively
(-49%) (P<0.00005 for both vs. preoperative baseline). Site of threshold measure failed to
have a significant effect on postoperative absolute threshold change, either singly or in
combination with other factors, thus it is not further considered in analysis. Increases and
decreases of absolute thresholds were most marked and significant for pain tolerance, less
so for pain detection, and not significant for sensation, thus only results for pain toler-
ance thresholds are displayed for the graphs of generalised sensory change. 
3.2.3. Changes with minor preoperative pain
In the placebo group, absolute thresholds taken together neither increased nor decreased
significantly during the first 24 hours postoperatively. They were significantly decreased
compared to preoperatively at 5 days after surgery. With preoperative fentanyl analgesia
there were no significant threshold changes at any time postoperatively. Overall thresh-
olds in the ketorolac group were significantly raised 1-4 hours postoperatively, and
decreased at 5 days post-surgery. Furthermore, thresholds in the ketorolac group were
lower than in the other two groups 24 hours to 5 days postoperatively. The postoperative
changes in absolute pain tolerance thresholds with minor preoperative pain are detailed
in the top half of Figure 1.
3.2.4. Changes with major preoperative pain
Placebo group absolute thresholds were not significantly altered at any time postopera-
tively. Fentanyl supplementation was associated with significant increases at 1 and 4
hours postoperatively, without subsequent decreases. In patients receiving ketorolac pre-
operatively, absolute thresholds taken together were unchanged 1-24 hours postopera-
tively; being decreased at 5 days compared to preoperatively as well as to the fentanyl
and placebo drug groups. The postoperative changes in absolute pain tolerance thresh-
olds with major preoperative pain are detailed in the bottom half of Figure 1.
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Change in absolute pain thresholds postoperatively (means, SD) in patients with minor (top) or major (bottom) preop-
erative pain receiving either placebo, fentanyl or ketorolac preoperatively. * = P<0.05 vs. control, † = P<0.05 vs. place-
bo group, ‡ = P<0.05 vs. fentanyl group.
Figure 1: Absolute thresholds with minor or major preoperative pain
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Figure 2: Relative thresholds with minor or major preoperative pain
Change in relative pain thresholds postoperatively (means, SD) in patients with minor (top) or major (bottom) preoper-
ative pain receiving either placebo, fentanyl or ketorolac preoperatively. * = P<0.05 vs. control, # = P<0.05 vs. patients
without pain, † = P<0.05 vs. placebo group.
3.3. Segmental sensory change: relative threshold values
3.3.1. Baseline values
Baseline values for relative thresholds did not differ according to drug group, site of
threshold testing or preoperative pain status. As covariant, preoperative thresholds were
significantly and inversely related to threshold changes during the entire postoperative
period (pooled within-groups correlations: 1h = -0.68, 2h = -0.77, 4h = -0.79, 6h = -0.83,
24h = -0.73, 5 days: -0.89). As expected, thresholds differed significantly according to the
type determined. 
3.3.2. Overall factor effects
Postoperative changes in relative thresholds were significantly affected by the single fac-
tors test type and time (Table 1). Relative threshold changes were most marked for (non-
nociceptive) sensation, not being significant for pain detection or tolerance, thus only
results for sensation thresholds are displayed for the graphs of spinal neuroplasticity. As
site of threshold measure had no significant effect on postoperative relative threshold
change, either singly or in combination with other factors, it is not further considered in
analysis.
3.3.3. Changes with minor preoperative pain
Relative thresholds overall were lower in the placebo group than in the other two drug
groups 4 and 24 hours postoperatively. Relative sensation thresholds in placebo patients
were significantly decreased compared to both preoperative baseline and the other two
groups 1 hour to 5 days postoperatively (Figure 2, top half). The lowest value was reached
24 hours postoperatively (-56%, P=0.00006 vs. preoperatively; fentanyl: +19%, ketoro-
lac: +6%, P=0.00006 both vs. placebo). Relative pain detection and tolerance thresholds
in all 3 groups remained unchanged throughout.
3.3.4. Changes with major preoperative pain
For placebo group patients, relative thresholds overall at 24 hours postoperatively were
significantly increased compared to both preoperative baseline and the ketorolac group.
There were no significant overall relative threshold changes compared to preoperative
baseline in the other two drug groups. The postoperative changes in relative sensation
thresholds with major preoperative pain are detailed in the bottom half of Figure 2.
3.4. Clinical pain measures
Cumulative PCA morphine consumption (Table 2) was significantly affected by the inter-
action of the factors drug group, preoperative pain status and time (P=0.02). Patients with
major preoperative pain receiving ketorolac used over twice as much morphine in 24
hours than those receiving fentanyl (P=0.003). Preoperative baseline pain scores in leg
and back were similar in the three drug groups (Table 3). Postoperative back pain scores
were similar between drug groups throughout. This was true both overall and analysing
patients with and without preoperative pain separately. However, for leg pain, patients
with major preoperative pain had significantly lower scores than those with minor pre-
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operative pain at 1, 4, and 6 hours postoperatively, without differences due to drug
group. Sedation scores did not differ at any time according to drug or pain group, and
median scores had returned to preoperative baseline values by 4 hours postoperatively.
4. DISCUSSION
This study shows that surgery in humans is followed by complex changes in central
nervous system sensory processing. The results of this study suggest the feasibility of
using quantitative sensory testing at multiple sites in the clinical surgical context to fol-
low the course of both generalised and segmental changes in central sensory processing,
with the former likely reflecting mainly supraspinal but also spinal effects, and the lat-
ter, spinal effects. As far as we are aware, our study is the first to investigate the diverse
effects of preoperative pain and preoperative analgesia on supraspinal and spinal
changes in central sensory processing at different phases of the postoperative process.
For patients with only minor pain preoperatively, surgery performed under volatile
general anaesthesia without analgesic supplementation and 24 hours of postoperative
morphine PCA analgesia is followed by segmental excitation lasting for the 5 days of the
study, with generalised spread of excitation (significant generalised hyperalgesia)
becoming apparent after 24 hours. The size of both the generalised and segmental
threshold changes is significantly and negatively correlated with preoperative threshold
levels. The presence of major pain preoperatively inhibits segmental (spinal) excitation,
with suppression of subsequent generalised hyperalgesia, too. Preoperative analgesic
supplementation with fentanyl suppresses both generalised and segmental facilitation,
also increasing acute early postoperative generalised inhibition in synergy with major
preoperative pain. The effects of ketorolac are more complex. Despite suppressing seg-
mental excitation, ketorolac is paradoxically associated with more generalised excitation
at 5 days. In addition, there is evidence of an antagonistic interaction between the acute
early postoperative generalised inhibition it causes and the presence of major preopera-
tive pain.
Patients with major pain before surgery had less pain in the leg during the early hours fol-
lowing surgery. More PCA morphine was used from 6 hours postoperatively onwards with
ketorolac as compared to fentanyl supplementation in patients with major preoperative pain.
The time course of postoperative clinical pain measures therefore only partially and incom-
pletely reflects the postoperative time course of alterations in central sensory processing as
demonstrated by threshold measures. Thus measures of altered sensory processing (e.g.
thresholds, quantitative sensory testing) provide new insight into postoperative pain mech-
anisms, and will likely need to be a necessary complement to clinical pain measures (e.g. pain
scores, analgesia use) in future investigation and management of perioperative nociception.
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4.1. Postoperative sensory change with minor preoperative pain and 
without analgesia
With minor preoperative pain and in the absence of preoperative analgesic supplemen-
tation of anaesthesia, we have demonstrated underlying segmental excitation up to 5
days postoperatively, accompanied by significant generalised hyperalgesia after the
first 24 hours. As investigation of these aspects of postoperative sensory change is still
in its very early stages, our discussion of the possible mechanisms involved will of
necessity be speculative. At least some of the continuing facilitation is likely to be the
result of ongoing wound nociception in the postoperative period. The waning of
supraspinal inhibition with increasing time after the start of nociception could also
contribute (Danziger et al., 2001). Another factor might be that morphine analgesia
during the first 24 hours, while being unable to completely suppress the establishment
of segmental excitation due to ongoing nociception, does prevent the rostral spread of
nociceptive excitation. This possibility is supported by the fact that segmental excita-
tion was mainly apparent in non-nociceptive processing (i.e. sensation thresholds), as
expected in view of the selective depression of nociceptive processing by opioids, par-
ticularly at the spinal level (van der Burght et al., 1994). After the end of morphine
analgesia, supraspinal spread of facilitation could then take place in this hypothesis,
leading to generalised hyperalgesia. A possible argument against such a scenario would
be the continuing presence of non-nociceptive - but not nociceptive - segmental facili-
tation at 5 days postoperatively. However, it could be that subsequent diclofenac analge-
sia, while being unable to block rostral facilitatory spread, is able to depress (mainly noci-
ceptive) segmental spinal facilitation up to day 5. Such an interpretation would be in
accordance with findings in the present study concerning ketorolac (also an NSAID),
which proved unable to block generalised facilitation despite inhibiting segmental facili-
tation (nociceptive more than non-nociceptive). It should be emphasised that these con-
siderations are at present speculative and that conclusive elucidation of mechanisms
involved awaits further studies.
4.2. Major preoperative pain and postoperative sensory change
Acute major preoperative pain in the absence of preoperative analgesic supplementation of
anaesthesia resulted in significant depression of postoperative segmental excitation and
absence of generalised hyperalgesia after 24 hours. In animal models, acute pain has been
demonstrated to elicit strong supraspinal inhibitory mechanisms which can effectively
inhibit spinal facilitation (Gall et al., 1999; Gozariu et al., 2000; Danziger et al., 2001). Major
preoperative pain may have sufficiently stimulated or activated inhibitory mechanisms to
depress spinal excitation due to intra- and early postoperative nociception, thus ultimately
preventing subsequent generalised hyperalgesia. The supraspinal inhibitory mechanisms
involved are likely to be distinct from diffuse noxious inhibitory controls (DNIC, which
originate in the caudal medulla (Bouhassira et al., 1995)) because in our study they are
increased with preoperative fentanyl (opioids reduce DNIC (Le Bars et al., 1992)). 
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4.3. Preoperative fentanyl and postoperative sensory change
Fentanyl supplementation preoperatively suppressed postoperative segmental excitation
and subsequent generalised hyperalgesia. In the presence of major preoperative pain it
also increased generalised hypoalgesia in the early postoperative hours. These effects are
in keeping with the well-documented spinal and supraspinal inhibitory actions of opi-
oids, which include positive interactions with various types of supraspinal stress- and
nociception-induced analgesia other than classic DNIC (Coderre et al., 1993; Grisel et al.,
1993; Woolfolk and Holtzman, 1993; Jayaram et al., 1995; Gozariu et al., 2000).
4.4. Preoperative ketorolac and postoperative sensory change
Postoperative segmental excitation was suppressed in patients receiving ketorolac.
Paradoxically, from 24 hours onwards significant generalised hyperalgesia was present,
greater than for placebo (or fentanyl) patients. In the presence of major preoperative pain,
early postoperative acute generalised inhibition was decreased, with less segmental inhibition
than in placebo patients at 24 hours. While NSAIDs have been shown to be able to suppress
spinal sensitisation (Malmberg and Yaksh, 1992; Bustamente et al., 1996), they may not be
able to prevent supraspinal spread of facilitation with overt generalised hyperalgesia after the
ending of morphine analgesia. This possibility is supported by reports that prostaglandin
synthesis inhibiting drugs such as NSAIDs can antagonise supraspinal stress- or nociception-
induced analgesia (Bhattacharya et al, 1978; Bustamente et al., 1997).
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time postop control 1h 2h 4h 6h 24h
Cumulative morphine PCA use (mg)
MINOR PREOPERATIVE PAIN
ketorolac 0 (0) 7.2 (2.6) 11.1 (6.5) 16.3 (8.3) 20.0 (8.1) 32.7 (15.1)
placebo 0 (0) 6.0 (2.0) 9.4 (3.3) 15.3 (5.3) 18.8 (6.5) 35.3 (12.6)
entanyl 0 (0) 6.0 (1.2) 9.4 (4.1) 15.1 (6.4) 19.5 (9.3) 42.0 (32.1) 
MAJOR PREOPERATIVE PAIN
ketorolac 0 (0) 5.5 (2.3) 11.0 (4.9) 16.9 (3.7) 21.8 (3.4) 59.1‡ (19.3)
placebo 0 (0) 6.3 (3.9) 10.2 (7.8) 13.8 (10.5) 16.9 (12.1) 32.7 (19.2)
fentanyl 0 (0) 7.6 (2.5) 12.4 (7.7) 21.6 (14.6) 23.3 (19.8) 25.3 (14.0)
Time course of postoperative cumulative morphine use (mg) by patient-controlled analgesia (PCA). Values are means
(standard deviations). ‡ = P<0.05 vs. fentanyl group.
Table 2: Postoperative morphine PCA consumption
4.5. Comparison with other studies
To the best of our knowledge, this is the first study to formally investigate the effects of
preoperative pain on postoperative changes in central sensory processing in the clinical
surgical context. Few other human studies of sensory change after surgery are available
at present. Early human studies demonstrate isolated segmental hyperalgesia to mechan-
ical or electrical stimulation (Dahl et al., 1993; Richmond et al., 1993) or generalised inhi-
bition using electrical stimulation (Willer et al., 1985; Lund et al., 1990; Peters et al.,
1992) once or twice postoperatively. Subsequent more detailed studies document the
presence of segmental excitation, abolished by opioid agonist or NMDA antagonist sup-
plementation, which also increases generalised hypoalgesia within the first 24 hours post-
operatively (Wilder-Smith et al., 1996; Wilder-Smith et al., 1998). 
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time postop control 1h 2h 4h 6h 24h 5d
LEG - Verbal pain intensity rating score (min = 0; max = 10)
MINOR PREOPERATIVE PAIN
ketorolac 0 (0-2) 2 (0-4) 1.5 (0-5) 0.5 (0-6) 0.5 (0-4) 0 (0-6) 0 (0-3)
placebo 0 (0-2) 2 (0-6) 2 (0-6) 2 (0-6) 0.5 (0-3) 1 (0-4) 1 (0-4)
fentanyl 0 (0-3) 2 (0-6) 0 (0-5) 0 (0-4) 0 (0-5) 1 (0-3 3 (2-5)
MAJOR PREOPERATIVE PAIN
ketorolac 4 (0-5) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-1)
placebo 6 (5-7) 0 (0-1) 2 (0-4) 0 (0-1) 0 (0-1) 1 (0-1) 1 (0-7)
fentanyl 7.5 (2-10) 1 (1-1) 0.5 (0-2) 0 (0-0) 0 (0-0) 0 (0-8) 0 (0-0)
BACK - Verbal pain intensity rating score (min = 0; max = 10)
MINOR PREOPERATIVE PAIN
ketorolac 0 (0-1) 3.5 (0-7) 2.5 (0-3) 2 (0-6) 1 (0-4) 1 (0-6) 0 (0-3)
placebo 0 (0-2) 5 (2-7) 3 (1-6) 2 (0-6) 2 (0-3) 2.5 (0-5) 1 (0-2)
fentanyl 0 (0-2) 4 (0-10) 3 (0-8) 3 (0-6) 3 (0-8) 1 (0-6) 1.5 (0-4)
MAJOR PREOPERATIVE PAIN
ketorolac 2 (0-5) 6 (5-7) 5 (3-8) 2 (1-5) 2 (2-4) 1 (0-3) 1 (1-1)
placebo 0 (0-7) 4 (3-8) 3 (2-5) 4 (2-5) 4 (3-6) 3 (2-5) 1 (1-1)
fentanyl 0 (0-5) 5 (1-8) 3.5 (0-7) 5 (0-5) 2.5 (0-7) 2.5 (0-10) 0 (0-2) 
Time course of verbal pain intensity rating scores in leg and back. Scores are medians (ranges).
Table 3: Postoperative verbal pain intensity scores in leg and back
4.6. Study design
The results of the study might have been influenced by the sensory testing paradigm,
considerations of statistical power, and postoperative drug effects. We chose electrical
stimulation because it is stable and reproducible, is easy to use and control clinically, has
a long history of utilisation and validation, and may be more sensitive to descending
inhibition than other modi (Maresca and Faccani, 1983; Lautenbacher and Rollman, 1993;
Wilder-Smith, 2000). A potential criticism is its non-physiological nature and the mixed
nerve fibre response it generally produces (dependent on stimulus characteristics), but
this could in fact be an advantage in the surgical context, where nociception also affects
multiple nerve populations. Patients were carefully instructed before inclusion into the
study about the sensory testing paradigm and underwent several test runs to minimise
variability. Possible sensitisation by electrical stimulation was curtailed by spacing test-
ing and stopping on reaching the pain tolerance threshold, and the effect of reaction time
minimised by slow ramping (0.1 mA.s-1). Some effects might not have been detected due
to insufficient sample size. Post hoc power testing shows that sample size was adequate
to detect clinically relevant differences of at least one third for thresholds and morphine
use. Regarding postoperative drug effects on thresholds, hangover from isoflurane or
nitrous oxide is unlikely to be of significance, as subanaesthetic isoflurane concentrations
have no effect on pain detection thresholds (Tomi et al., 1993), and the effects of nitrous
oxide on the same continue for about 30 minutes after discontinuation (Ramsey et al.,
1992). Opioids (e.g. morphine, fentanyl) have no or minimal direct effects on sensation or
pain detection thresholds, with effects on pain tolerance thresholds being most marked
for long and/or repeated stimulation (van der Burght et al., 1994; Liu et al., 1996).
Diclofenac has smaller effects than opioids on threshold testing, but has been shown to
raise electric and thermal tonic pain tolerance thresholds (Stacher et al., 1986). Effects due
to either of the postoperative analgesics are unlikely to explain group threshold differ-
ences, however, due to their generally similar usage in all groups. The only exception is
the markedly higher morphine use at 24 hours in the ketorolac group (vs. fentanyl) with
major pain - here one would expect the ketorolac group to have a markedly higher thresh-
old than the fentanyl group, but this is in fact not the case, tending to rule out morphine
as an explanation of this difference. A further potential confounding factor could be dif-
ferences in pain scores at the time of measure. To our knowledge, such effects have not
been formally investigated to date, however, as pain scores were similar in the groups at
all times after 6 hours postoperatively, this is unlikely to explain subsequent group dif-
ferences in thresholds.
4.7. Postoperative sensory change and clinical pain measures
As in previous reports investigating both measures of sensory change and clinical pain
after human surgery (Wilder-Smith et al., 1996; Wilder-Smith et al., 1998), the time course
of the latter only partially and incompletely reflects that of the former. In this context, it
appears that generalised changes in sensory processing affect clinical pain measures more
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than do segmental changes. This is in conformity with recent reports as to serial aspects of
nociceptive processing, particularly regarding pain intensity and affective aspects of the
pain experience (Price, 2000). The relative lack of sensitivity of clinical pain measures to
post-nociceptive changes in central sensory processing is furthermore hardly surprising in
view of the accepted multifactorial origin and subjective nature of the individual experi-
ence of pain, and confirms the necessity of collecting direct measures of sensory change if
the mechanisms of surgical nociception and its modulation are to be understood.
4.8. Implications for clinical practice and future research
A shift from symptom-based approaches to postoperative pain to mechanism-based man-
agement of postoperative nociception will only be achieved on the basis of a thorough
understanding of the mechanisms involved. Our current results suggest that clinical pain
measures alone are unlikely to prove adequate in this context as they only partially and
incompletely reflect post-nociceptive changes in central nervous system processing, par-
ticularly at the spinal level. As nociceptive processing progresses rostrally in the central
nervous system from the spinal level, the pathway ending in subjective and affective
aspects of the pain experience involves processing in a serial, consecutive fashion, while
the path to autonomic and metabolic arousal entails parallel, direct processing access
(Price, 2000). Any outcome changes due to perioperative antinociceptive therapy, are,
however, likely to be achieved via modulation of effects consequent to autonomic and
metabolic arousal. Thus outcome-effective therapeutic intervention will have to be based
upon an understanding and monitoring of more caudal changes in central nervous sys-
tem sensory processing. This can only reliably be provided by direct measures of central
sensory change. In view of this, and in view of the demonstrated complexity of central
changes in sensory processing and its interaction with modulating factors such as pain
and analgesia, we propose that future research - and clinical practice - needs to include
measures of sensory change as provided, e.g., by quantitative sensory testing.
4.9. Conclusions
In conclusion, the present study shows that the basic response of central nervous system
sensory processing to human surgery is one of segmental excitation followed later by gen-
eralised excitation, perhaps as the result of morphine analgesia ending and early acute
supraspinal inhibitory controls fading. The presence of acute major pain preoperatively
suppresses segmental sensitisation and subsequent generalised excitation, perhaps via
the elicitation of acute supraspinal inhibitory mechanisms. Fentanyl analgesia too pre-
vents segmental and subsequent generalised excitation, synergising with the effects of
major preoperative pain. Ketorolac before surgery also blocks postoperative segmental
excitation, but paradoxically does not prevent the appearance of late generalised excita-
tion, perhaps due to antagonistic interactions with supraspinal inhibitory systems. These
changes in central sensory processing are only partially manifest in clinical pain meas-
ures, suggesting the need to include direct measures of sensory change, e.g. via QST, in
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future research and clinical practice concerning perioperative nociception. The interac-
tions between endogenous and exogenous modulation of sensory change in the context
of surgical nociception, and their relationship to clinical pain and surgical outcomes,
require further detailed investigation.
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16. SUMMARY - TOWARDS A SYSTEMATIC ACCOUNT 
OF SURGICAL NEUROPLASTICITY
The six studies presented here represent a first systematic attempt to explore the post-
operative neuroplasticity accompanying human surgery using a simple quantitative sen-
sory testing (QST) paradigm, specifically adapted to the clinical context, involving ther-
mal or electric stimulation of the skin. The studies allow first conclusions to be drawn
regarding the time course of post-surgical neuroplasticity, its excitatory as well as
inhibitory elements, the relative contributions made by spinal and supraspinal respons-
es, and the effects of both intrinsic and extrinsic factors typically encountered in the sur-
gical context. In addition, the present investigations permit further insights to be gained
concerning the complex relationships between measures of the subjective pain experi-
ence and measures of the objective changes in central nervous system processing after
surgical nociception. Finally, by virtue of the number of patients undergoing QST meas-
urement in these studies, we can also draw conclusions as to the feasibility and practica-
bility of performing such measures in the context of clinical routine.
The studies included in this section represent some 23000 individual threshold measures
performed in over 200 patients for QST in the context of routine clinical surgery. In all of
these studies, threshold measure variability during one QST session had to be less than
20%, otherwise the session had to be repeated, a condition which did not occur in any
of the patients included in these studies. In addition, no patient refused to continue tak-
ing part in QST testing once they had been included in a study, demonstrating that rela-
tively simple training for QST testing of this nature was adequate for our study purpos-
es. Both thermal and electrical skin threshold testing are feasible in the clinical context,
with electrical stimulation, the less physiological of the stimuli, proving to be less com-
plicated to perform in practice and permitting a higher temporal and spatial density of
measurements. The studies show that tonic/pain tolerance thresholds provide the best
reflection of surgical nociceptive neuroplasticity and its modulation by a variety of clin-
ically typical factors.
Taking all of these facts together, we would suggest that the QST paradigms we devel-
oped are practical for demonstrating nociceptive neuroplasticity in the clinical surgical
environment. Two points need to be made in this context. Firstly, the interindividual vari-
ability of the thresholds proved to be relatively high, which is in keeping with other
studies using QST (or neuroelectrophysiological methods) (1,2), and which is probably
due to the highly variable nature of the genetic factors controlling nociceptive sensory
processing (3). Secondly, the results obtained show the feasibility of separating spinal
from supraspinal neuroplasticity by normalising thresholds close to surgery by reference
(e.g. division) to thresholds distant from surgery.
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16.1. Nature and Time Course of Post-Surgical Neuroplasticity
Using patients which are pain-free before surgery and who receive volatile anaesthesia
without analgesic supplementation during surgery as the control (or comparator) condi-
tion, we have been able to demonstrate the following basic neuroplastic changes after sur-
gery (Figure 1):
16.1.1. Supraspinal (Generalised) Neuroplasticity
Up to 24 hours postoperatively, our patients showed threshold increases of up to 50%.
These increases were most prominent for pain detection thresholds, maximal ca. 4 hours
postoperatively and greater in the surgical dermatomes (4,5). Thresholds returned to pre-
operative baseline around 24 hours after surgery. By five days postoperatively, gener-
alised hyperalgesia (i.e. thresholds reduce compared to preoperatively) was present. The
preoperative threshold values had a significant effect on postoperative threshold values
over the entire time course of the study. 
16.1.2. Spinal (Segmental) Neuroplasticity
Our control patients show reductions in spinal thresholds (i.e. segmental, normalised vs.
arm thresholds) throughout the postoperative period of up to ca. 50%. They were affect-
ed by preoperative threshold values only in the early postoperative period (4,5). These
effects are only significant in non-nociceptive sensation thresholds, perhaps due to the
known direct spinal effects of post-operative morphine analgesia on pain detection and
pain tolerance thresholds, particularly in the presence of previous sensitisation (6).
16.1.3. Summary
In the absence of preoperative pain or analgesic supplementation, surgery results in long-
lasting spinal excitation. Early postoperative supraspinal inhibitory neuroplasticity, max-
imal for C-fibre nociception, in traumatised dermatomes and at ca. 4 hours, is followed
Figure 1: Surgical nociceptive neuroplasticity: no preoperative pain, no analgesic supplementation. Left: supraspinal
neuroplasticity, change in absolute pain tolerance thresholds (mA). Right: spinal neuroplasticity, change in relative sen-
sation thresholds (ratio).
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later by generalised supraspinal excitatory neuroplasticity, still visible at day 5, and also
maximal for C-fibre nociception and dermatomes subject to surgery. Our findings suggest
that up to 24 hours postoperatively, supraspinal inhibition and morphine analgesia are
able to suppress the supraspinal expression of excitatory neuroplasticity due to surgical
nociception. Supraspinal spread of excitation then takes place, becoming visible as
supraspinal hyperalgesia on day 5. 
16.2a. How Does Analgesia Affect Postoperative Neuroplasticity?
We examined the effects of both neuraxial and systemic analgesia on post-surgical neu-
roplasticity in the absence of preoperative pain (Figure 2). The substances included in the
studies were opioids (fentanyl, sufentanil), mixed opioid and monoamine agonists (tra-
madol), NMDA-blockers (ketamine, magnesium), and NSAIDs (ketorolac).
16.2a.1. Supraspinal (Generalised) Neuroplasticity
The pre- and intraoperative use of systemic fentanyl tends to result in synergistic
increases in early postoperative increases in pain thresholds, and abolishes threshold
reductions on day 5 (4,5,7). Systemic ketamine anaesthetic supplementation also raises
early postoperative pain thresholds compared to preoperatively (more so than fentanyl),
and is not associated with threshold reductions on day 5, although day 5 thresholds are
lower absolutely than in fentanyl-complemented patients (7). The effects of systemic
magnesium supplementation are similar to, but smaller than those of ketamine (7).
Adding intravenous ketorolac to anaesthesia also results in increased early threshold
rises, without, however, suppression of large late, day 5 decreases in pain thresholds (5).
Postoperative epidural sufentanil (8) is associated with increased early (non-segmental)
pain thresholds, while high doses of preoperative adjuvant epidural tramadol (9) result
in long-lasting (up to 48 hours) postoperative pain threshold increases. The threshold
changes in both epidural groups were determined far from the site of surgery and the seg-
 
Figure 2: Surgical nociceptive neuroplasticity: no preoperative pain, but with analgesic supplementation. Left:
supraspinal neuroplasticity, change in absolute pain tolerance thresholds (mA). Right: spinal neuroplasticity, change in
relative sensation thresholds (ratio).
ment of epidural catheter placement. In both epidural studies, pain thresholds were sensi-
tive to excitatory drug effects. Comparing control (placebo) patients receiving approximate-
ly equipotent postoperative opioid intravenous PCA, the early postoperative increases in
pain thresholds during PCA tramadol were smaller than those with PCA morphine (4,5,9).
16.2a.2. Spinal (Segmental) Neuroplasticity
All four systemic analgesic substances suppress postoperative reductions in spinal
thresholds, with fentanyl showing a tendency to be associated with small rises in spinal
thresholds (4,5,7). We did not test for segmental neuroplasticity with the epidural anal-
gesics (8,9) due to the confounding effects of epidural local anaesthetic blockade.
16.2a.3. Summary
In the absence of preoperative pain, all analgesic anaesthetic supplements tested showed
some synergistic increases in early postoperative supraspinal inhibitory neuroplasticity.
The systemic substances investigated were similarly able to suppress postoperative spinal
excitatory neuroplasticity. Despite suppressing spinal sensitisation, the NSAID ketorolac
was not able to suppress late supraspinal hyperalgesia, being associated with significant
late hyperalgesia comparable in degree to that seen without analgesic supplementation.
However, both opioids and NMDA-antagonists did prevent subsequent late, day 5 post-
operative supraspinal hyperalgesia, confirming predictions based on animal data that the
impact of intraoperative analgesia (i.e. pre-emptive analgesia) on nociceptive neuroplas-
ticity is much greater than that of postoperative analgesia. Based on the supposition that
early postoperative hypoalgesia is dependent on the acute nociceptive input of surgery,
the lesser early hypoalgesia in the control PCA tramadol patients as compared to the con-
trol PCA morphine patients is most likely due to the fact that the tramadol patients
received epidural anaesthesia, whereas the morphine patients had (“non-analgesic”)
volatile general anaesthesia. This would again support the major importance of intraop-
erative antinociception in determining postoperative central neuroplasticity.
16.2b. How Does Preoperative Pain Affect Postoperative Neuroplasticity?
We found the presence of preoperative pain to be associated with significant neuroplastic-
ity (10). Acute sciatic pain resulted in inhibitory neuroplasticity, while more chronic back
pain was associated with excitatory neuroplasticity. Only for sciatica was there a signifi-
cant, negative relationship between pain scores and pain thresholds. Regarding patients
with acute preoperative pain and not receiving analgesic supplementation of anaesthesia for
their surgery (5), we found the following changes in central sensory processing (Figure 3):
16.2b.1. Supraspinal (Generalised) Neuroplasticity
Patients with preoperative acute pain - and without intraoperative analgesia - had no late
day 5 decreases in pain thresholds compared to preoperatively (5). The early increases in
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pain thresholds were smaller than in patients without preoperative pain. Preoperative
thresholds in these patients were significantly and negatively correlated to thresholds 1
and 5 days postoperatively.
16.2b.2. Spinal (Segmental) Neuroplasticity
Patients with preoperative acute pain and without intraoperative analgesia showed no
decreases in spinal pain thresholds compared to preoperatively (5). At 24 hours postop-
eratively, spinal thresholds were increased compared vs. preoperatively. Preoperative
spinal thresholds correlated significantly and negatively to postoperative ones through-
out the postoperative period.
16.2b.3. Summary
Acute preoperative pain (e.g. sciatica) is associated with inhibitory supraspinal neuro-
plasticity preoperatively, and suppression of both spinal and subsequent supraspinal
excitatory neuroplasticity postoperatively. It should be noted that patients with acute leg
pain preoperatively had less early leg pain postoperatively.
16.2c. How Do Analgesia and Preoperative Pain Interact to Affect
Postoperative Neuroplasticity? 
Analgesic supplementation of anaesthesia with fentanyl as well as ketorolac was found to
interact with the presence of acute pain preoperatively (5) (Figure 3):
16.2c.1. Supraspinal (Generalised) Neuroplasticity
Fentanyl supplementation in the presence of acute preoperative pain resulted in a ten-
dency to greater early postoperative increases in pain thresholds as compared to patients
without pain, while ketorolac supplementation was associated with smaller increases (5).
As before, fentanyl abolished late (day 5) postoperative threshold decreases, while ketoro-
lac supplementation was associated with large decreases in pain thresholds on day 5.
16.2c.2. Spinal (Segmental) Neuroplasticity
Spinal threshold decreases as compared to preoperative values were completely sup-
pressed by fentanyl (5). Ketorolac supplementation was also associated with inhibition of
spinal threshold decreases, albeit less so than in patients without analgesic supplementa-
tion or with fentanyl supplementation at 24 hours postoperatively (5). 
16.2c.3. Summary
Adding fentanyl to anaesthesia generally interacts positively with the presence of preop-
erative acute pain in preventing excitatory neuroplasticity, both spinal and supraspinal,
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and in augmenting early postoperative supraspinal inhibition. Ketorolac anaesthetic sup-
plementation in patients with acute preoperative pain has negative consequences in that
early inhibitory supraspinal neuroplasticity is reduced and the blocking effect of acute
preoperative pain on late (day 5) postoperative supraspinal hyperalgesia is abolished. It
should be noted that in the presence of acute pain preoperatively, ketorolac-supplement-
ed patients used one third more morphine by patient-controlled analgesia than did fen-
tanyl-supplemented ones.
16.3. What Is the Relationship between Postoperative Neuroplasticity
and Clinical Pain Measures?
Taking the studies presented here together (4,5,7-10), it is obvious that the relationship
between various aspects of post-surgical central neuroplasticity and pain is a complex and
multifactorial one. The neuroplastic changes seen in the various investigations discussed
here are in general weakly and incompletely reflected by either pain scores or postopera-
tive analgesia consumption. Thus measures of neuroplasticity and pain after surgery
should be seen as providing complementary information, with the latter not being able to
replace the former - or vice versa. Better understanding of the relationship between pain
and neuroplasticity after surgery awaits further studies undertaking formal investigation
of correlations between these factors as well as including larger patient numbers.
16.4. Implications: QST in Clinical Practice for Diagnosing Nociceptive
Neuroplasticity
Both the advantages of using QST for demonstrating surgical nociceptive neuroplasticity
as well as the disadvantages of not using such a technique support its introduction into
clinical practice. As elucidated here, the advantages include that QST is relatively easy to
establish in clinical practice, that it provides a defined, more objective measure of noci-
ceptive surgical neuroplasticity, and that it is sensitive to factors clinically relevant for sur-
gical nociception and its management. The price of not introducing QST for nociceptive
neuroplasticity monitoring into clinical practice is that without such an endpoint, we have
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Figure 3: Surgical nociceptive neuroplasticity: with preoperative pain, and with analgesic supplementation. Left:
supraspinal neuroplasticity, change in absolute pain tolerance thresholds (mA). Right: spinal neuroplasticity, change in rel-
ative sensation thresholds (ratio).
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no basis for achieving the shift from symptom-based to mechanism-based management
strategies for surgical nociception. Without a measure of nociceptive neuroplasticity we
have neither information on the mechanisms possibly involved nor a feedback measure for
the therapeutic intervention instituted. Thus we would suggest that we have demonstrat-
ed that QST is feasible for demonstrating nociceptive neuroplasticity in clinical practice,
that it provides information on the mechanisms involved in surgical nociception useful for
both diagnostic and therapeutic purposes, and that it consequently warrants introduction
into clinical research and practice for surgical nociception management.
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19. QUANTITATIVE SENSORY TESTING AND NEUROPLASTICITY: 
IMPLICATIONS FOR SURGICAL PAIN MANAGEMENT
The research presented here permits, we would suggest, the drawing of a number of con-
clusions relevant to surgical pain and nociception and its medical management. The first
set of conclusions pertains to things which can now be considered reasonably well-
proven and which could thus be applied to medical practice now, while the second set
concerns future development and research in this area. It must be emphasised in this con-
text that quantitative sensory testing (QST) monitoring of surgical nociceptive neuro-
plasticity for nociception management is at an early stage. Considerable development and
research are necessary to fully understand and validate this area and it practical implica-
tions, but it would appear that its application carries the promise of introducing a new
level of understanding to the management of surgical nociception. In this final chapter
we will attempt to provide a brief overview of the implications of our investigations, both
present and future.
19.1. Immediate Implications for Clinical Practice
19.1.1. Feasibility of QST Use in the Clinical Context
The body of research introduced here reports a large number of QST measures in routine
patients in the clinical setting. Electrical threshold determinations in this context were
well-accepted, and proved relatively simple and rapid regarding both instruction and
actual measures. The equipment (nerve stimulator, self-adhesive ECG electrodes) is sim-
ple and affordable. At present, thermal (Peltier thermode) thresholds are less practicable,
being more onerous to obtain. Although the widespread introduction of routine clinical
QST awaits development of the equipment used, we would consider that, with appropri-
ate training and organisation, electrical stimulation techniques can be directly introduced
into clinical practice now for selected patients.
19.1.2. Effectiveness of QST for Demonstrating Analgesia and Surgical
Neuroplasticity
In all of the investigations presented here, it proved possible to show, follow and differ-
entiate the changes in sensory processing (i.e. neuroplasticity) accompanying analgesia
and surgical nociception. Thus the QST methods presented are an effective means of mak-
ing surgical neuroplasticity visible in the clinical context. QST offers the prospect of a
useful new endpoint for the management of surgical pain and nociception, with a real
potential for providing novel, objective information. Such knowledge about surgical neu-
roplastic change - and thereby about underlying mechanisms of nociception -is both rel-
evant to clinical management and not obtainable by established clinical methods.
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19.1.3. QST vs. Clinical Pain Measures in Surgical Pain and Nociception
Management
The neuroplasticity demonstrated to accompany surgery in our studies is generally only
weakly and indirectly reflected in clinical pain measures such as pain scores or analgesia
use. This is not surprising in view of the of the complexity of subjective pain experience,
with its multifactorial nature, mechanisms and aetiologies (1,2) and involving many fac-
tors quite unrelated to the original nociceptive stimulus. The investigations under dis-
cussion here clearly show that clinical pain measures are not a reliable or complete indi-
cator of underlying changes in central nervous system sensory processing, and thus of
the mechanisms involved in the production of surgical pain. Clinical pain measures and
QST results must therefore be regarded as providing different but complementary kinds
of information useful in the management of surgical pain and nociception.
19.1.4. Nature of the Surgical Neuroplasticity Demonstrated by QST
Our results illustrate the complexity of the neuroplastic response to surgical nociception.
We have shown and detailed the complexity to comprise a number of aspects, including
mechanisms (e.g. excitatory vs. inhibitory), structures involved (e.g. spinal vs.
supraspinal) and time course (e.g. acute vs. subacute). If we are to properly understand
surgical neuroplasticity in a specific patient or situation, it is clearly important for all
these aspects to be taken into account and made visible by the QST methods employed.
We would suggest that the QST design features presented in our studies, particularly
regarding stimulus characteristics, topographical and temporal aspects, represent the
minimum necessary to achieve an acceptable understanding of the complex neuroplastic
response to surgical nociception. The question of the desirability and practicability of
including multiple stimulus modalities (e.g. thermal, mechanical, electrical) awaits future
studies.
19.1.5. Towards more Effective Surgical Pain Management
QST is the basis for the necessary shift to mechanism-based surgical pain management by
providing useful insight into the mechanisms associated with surgical nociception and its
management in a number of ways. Firstly, it provides a way of differentiating nociceptive
alterations in the function of - and the balance between - different parts of the central
nervous system (e.g. spinal vs. supraspinal, excitation vs. inhibition) in a way which
global clinical pain measures never can. Secondly, by allowing quantification of changes
in lower-order (i.e. more caudal) sensory processing, it takes us much closer to the noci-
ceptive load the body experiences, and thus potentially to metabolic, immunological or
trophic consequences for the body as a whole. Finally, QST in our studies is sensitive to
modulation of the neuroplastic response to nociception by both intrinsic and extrinsic
factors. Thus it is possible to make visible the mechanisms by which such factors (e.g.
various analgesic drugs) affect surgical pain and nociception. Attention must be called
here to the hitherto largely neglected but important role which intrinsic inhibitory
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mechanisms play in the neuroplastic response to surgical nociception, pointing to the
need to include management of intrinsic inhibitory responses in future therapeutic anal-
gesic strategies. Thus, use of QST-demonstrated nociceptive neuroplasticity brings with
it not only the potential for understanding the mechanisms underlying the pain of sur-
gery, but also of providing a defined, more objective, mechanism-based endpoint for the
rational choice and control of existing - and new - drug or other measures in surgical
nociception management. Immediate practical consequences for such management would
include starting effective (e.g. opioid or NMDA-receptor-based) analgesia before surgery
and to continue with it into the postoperative period, as well as the need to take into
account endogenous antinociceptive inhibitory responses in the planning of periopera-
tive analgesia (e.g. the effects of preoperative pain or ketorolac therapy).
19.2. Future Implications for Development and Research
19.2.1. Development: Integrating QST into Routine Clinical Management of
Surgical Nociception
In order to maximise benefit from the advantages of mechanism-based as opposed to
symptom-based management of surgical nociception, an effort will be needed to ensure
its broader introduction into routine clinical practice. In this context, two measure will
be of importance: Firstly, the practicability of using QST in the clinical context will have
to be increased via further development and validation of testing paradigms and the
equipment used. In this context automation of both testing and data collection via appro-
priate application of computer technology will play an important role. Secondly, system-
atic research will have to be undertaken to identify the patient subgroups most likely to
benefit from QST/mechanism-based management of surgical nociception, both as a group
and as individual patients. This would involve identification of patients/groups especial-
ly vulnerable to undesirable surgical neuroplasticity and pain outcomes, and those par-
ticularly likely to benefit from targeted, mechanism- and QST-based nociception manage-
ment strategies.
19.2.2. Research: QST, Mechanism-based Nociception Management and
Disease Outcomes Modification
Nociceptive neuroplasticity is also considered to be the basis for - and an integral part
of - the chronification process leading to the progression of acute pain to various chron-
ic pain syndromes (3-5). In this context, the application of QST and mechanism-based
pain management may prove useful both in identifying the mechanisms involved in
chronification, and in conceiving strategies for preventing or modulating the chronifi-
cation process. The neuroplastic changes having been shown to take place after surgery
are of the type considered to be involved in pain chronification mechanisms (3,4,6,7).
Therefore the demonstration that certain types of pre-emptive analgesia can inhibit such
changes in sensory processing represents a first step in the elucidation of promising
strategies for preventing pain chronification. There is clearly a need for studies investi-
gating the course of neuroplastic changes after surgical (or other) nociception, as well as
the effect of putative mechanism-based preventive management strategies, over a much
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longer time-frame than at present available. Furthermore, as discussed above, nocicep-
tive neuroplasticity is likely to be much closer to original nociceptive load and hence
outcome-relevant metabolic, immunological and trophic effects. Thus future studies in
this field will also have to investigate the relevance of QST-derived neuroplasticity to
long-term outcomes of surgery, and the possibilities of modulating these via appropriate
nociceptive management.
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SHORT ENGLISH SUMMARY
Nociception, including that caused by surgery, is associated with changes in peripheral
and central nervous system processing. This neuroplasticity is considered an important
mechanism for pain after surgery, both acute and chronic. However, despite greatly
increased theoretical understanding from animal work linking nociceptive biomolecular
mechanisms and neuroplasticity, the clinical management of surgical pain continues to
represent a major practical challenge. Because adequate pain management has the poten-
tial to reduce postoperative morbidity and improve surgical outcomes, this challenge
clearly warrants action. 
It would appear logical that therapeutic management of surgical pain is most successful
if based on an understanding and knowledge of the mechanisms acting during surgical
nociception. However, at present virtually all therapeutic management of surgical pain
and nociception is based upon subjective clinical pain symptomatology and measures.
There is thus a clear need for the development of defined, more objective, clinically use-
ful measures upon which to base the shift from symptom-orientated to mechanism-based
pain management. The aim of this work is to provide the basis for such a shift by vali-
dating nociceptive neuroplasticity as an objective and feasible endpoint for surgical noci-
ception and its therapy. 
We have addressed this aim in a number of ways. After the introductory user’s guide in
Section I, Section II provides a theoretical background to our subsequent research. We
provide animal data linking nociception, biomolecular mechanisms and neuroplasticity
(chapter 2), discuss the practical aspect of the measure of nociceptive neuroplasticity by
quantitative sensory testing (QST) as well as its relationship to pain (chapter 3), and intro-
duce a detailed plan and rationale for the research to be presented (chapter 4). 
In the subsequent two sections (Sections III-IV), we portray the results and application
of our research using QST for quantifying analgesia and surgical neuroplasticity. First,
in Section III, we validate QST for monitoring altered sensory processing in the simpler
context of investigating analgesia. Here we present studies demonstrating the antinoci-
ceptive properties of both intravenous anaesthetics (chapter 6) and opioid analgesics
(chapter 7) by QST using thermal or electrical stimulation. Subsequently, in Section IV,
we report the results of our systematic investigation of surgical nociceptive neuroplas-
ticity using QST (chapters 10-15). On the basis of these studies involving over 200
patients we demonstrate the feasibility of using QST in the clinical context.
Furthermore, we show that the use of the objective endpoints of nociceptive neuroplas-
ticity provides novel information which is clinically useful and not obtainable by other
means such as subjective pain measures (summary in chapter 16). In particular we show
that surgical nociception is followed by a complex neuroplastic response which varies
over time, and which involves both excitation and inhibition of spinal and supraspinal
origin. Interestingly, preoperative pain is also associated with neuroplasticity, and the
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inhibitory neuroplasticity accompanying acute preoperative sciatica is seen to reduce
postoperative excitatory neuroplasticity for up to 5 days. Perioperative analgesia gener-
ally exerts a positive effect in reducing excitatory postoperative neuroplasticity,
although the details of these effects vary according to drug, mode of application and
time. Postoperative neuroplasticity is only weakly and incompletely reflected by clini-
cal pain measures such as pain scores or analgesia use. 
The last two sections (Sections V-VI) discuss practical applications and implications of
QST and nociceptive neuroplasticity for surgical pain and nociception management.
Section V includes two review articles discussing the impact of the concept of nocicep-
tive neuroplasticity on the long-standing pre-emptive analgesia debate (chapter 17) and
practical aspects of QST use in the surgical context (chapter 18). In summing up, chapter
19 addresses the question of the applicability and impact of QST and nociceptive neuro-
plasticity on the present and future practice of perioperative pain management. QST can
feasibly be introduced into clinical practice now as a means of objectively monitoring
nociceptive neuroplasticity, thus commencing the transfer from symptom-orientated to
mechanism-based pain management. In future, much more use will have to be made -
both in research and clinical practice - of its unique potential to provide information not
obtainable by classic measures of the subjective pain experience. Here, a particularly
promising application will be the concept of nociceptive load modulation to alter long-
term pain and medical outcomes after surgery or other painful conditions.
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SHORT DUTCH SUMMARY
Nociceptie, ook ten gevolge van operatief ingrijpen, gaat gepaard met veranderingen in
de werking van het perifere en centrale zenuwstelsel. Deze veranderingen, ook wel
neuroplasticiteit genoemd worden beschouwd als een belangrijk mechanisme bij het ont-
staan van zowel acute als chronische pijn na een operatie. Ofschoon de theoretische ken-
nis gebaseerd op dierexperimenteel onderzoek waaruit blijkt dat biomoleculaire mecha-
nismen en neuroplasticiteit met elkaar in verband staan aanzienlijk is toegenomen, blijft
de klinische behandeling van chirurgische pijn een grote uitdaging. Aangezien een ade-
quate behandeling van deze pijn mogelijk postoperatieve morbiditeit kan reduceren en
de chirurgische resultaten kan verbeteren, is het van belang deze uitdaging aan te gaan. 
Het lijkt logisch dat de behandeling van chirurgische pijn het meest succesvol zal zijn als
deze gebaseerd is op kennis van de mechanismen betrokken bij de (chirurgische) noci-
ceptie. Echter, op dit moment zijn bijna alle behandelingen van deze pijnklachten geba-
seerd op subjectieve, klinische symptomen en metingen. Er is dus een duidelijke behoef-
te aan de ontwikkeling van objectieve, klinisch bruikbare metingen waarop men de over-
gang van een symptoom georiënteerde naar mechanisme gerichte pijnbehandeling kan
baseren. Het doel van dit onderzoek is daarom de basis te leggen voor deze overgang door
nociceptieve neuroplasticiteit te valideren als een objectief en bruikbaar eindpunt voor
de gevolgen van chirurgische nociceptie en therapie.
Wij hebben deze vraagstelling op een aantal verschillende manieren benaderd. In sectie II
wordt de theoretische achtergrond voor dit onderzoek weergegeven. Wij presenteren resul-
taten van dierexperimenteel onderzoek welke nociceptie, biomoleculaire mechanismen en
neuroplasticiteit met elkaar in verband brengen (hoofdstuk 2). Verder worden de praktische
aspecten van het meten van nociceptieve neuroplasticiteit door kwantitatieve sensorische
toetsing (QST) en ook de relaties tussen QST en pijn besproken (hoofdstuk 3). Een gede-
tailleerd plan en de redenen voor het onderzoek worden gepresenteerd in hoofdstuk 4.
In de volgende twee secties (secties III-IV) worden de resultaten en toepassingen gepre-
senteerd van ons onderzoek waarin QST wordt gebruikt voor de kwantificering van
analgesie en chirurgische neuroplasticiteit. Ten eerste (sectie III) valideren wij QST om
de veranderde sensorische verwerking te meten in relatie tot het effect van analgetica.
Hier worden studies geïntroduceerd die de antinociceptieve eigenschappen van zowel
intraveneuze anesthetica (hoofdstuk 6) als ook opioide analgetica (hoofdstuk 7) teweeg-
brengen via QST door thermische of elektrische stimulatie. Vervolgens, in sectie IV, wor-
den de resultaten van ons systematisch onderzoek over chirurgische nociceptieve neuro-
plasticiteit met QST gerapporteerd (hoofdstukken 10-15). Op basis van deze studies met
meer dan 200 patiënten demonstreren wij de uitvoerbaarheid van QST in de klinische
context. Bovendien wordt aangetoond dat het gebruik van de objectieve eindpunten van
nociceptieve neuroplasticiteit nieuwe informatie geeft welke klinisch bruikbaar is en
niet op andere manieren zoals door subjectieve pijn metingen verkregen kan worden
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(samenvatting in hoofdstuk 16). In het bijzonder wordt aangetoond dat chirurgische
nociceptie gevolgd wordt door een complexe neuroplastische reactie die in de tijd vari-
eert en die zowel excitatie als ook inhibitie van spinale en supraspinale systemen betreft.
Van belang is het feit dat preoperatieve pijn ook geassocieerd is met neuroplasticiteit.
Deze zogenaamde inhiberende neuroplasticiteit welke acute preoperatieve ischialgie
(“sciatica”) begeleidt, kan vervolgens postoperatieve excitatoire neuroplasticiteit over
een periode van 5 dagen reduceren. Perioperatieve analgesie oefent in het algeheel een
positief effect uit op het reduceren van excitatoire postoperatieve neuroplasticiteit.
Echter de exacte effecten hangen af van het toegediende medicament, de wijze van
gebruik en de tijdsduur. Postoperatieve neuroplasticiteit wordt alleen beperkt en incom-
pleet weergegeven door klinische pijn metingen zoals pijn scores of het gebruik van
analgetica. 
De laatste twee secties (secties V-VI) behandelen praktische toepassingen en implicaties
van QST en nociceptieve neuroplasticiteit voor de behandeling van chirurgische pijn en
nociceptie. Sectie V omvat twee overzichtsartikelen die de invloed van het concept van
nociceptieve neuroplasticiteit bespreken zowel met betrekking tot de langdurig aanhou-
dende discussie over “pre-emptive analgesia” (hoofdstuk 17) als met betrekking tot prak-
tische aspecten van QST gebruik in de chirurgische context (hoofdstuk 18).
Samenvattend bespreekt hoofdstuk 19 de huidige en toekomstige vragen over de prakti-
sche uitvoerbaarheid en de effecten van QST en nociceptieve neuroplasticiteit op de
praktijk van de perioperatieve behandeling van pijn. QST kan nu haalbaar geïntrodu-
ceerd worden in de klinische praktijk als een manier om nociceptieve neuroplasticiteit
objectief te meten om zo een begin te maken van de overgang van een symptoom geori-
ënteerde naar een mechanisme gerichte pijn behandeling. 
In de toekomst zal meer gebruik gemaakt moeten worden - zowel in onderzoek als klini-
sche praktijk - van deze unieke mogelijkheid om informatie te verkrijgen welke niet door
klassieke subjectieve pijn metingen verschaft kan worden. Wanneer die situatie is bereikt
zal de modulatie van nociceptieve mechanismen, met als doel een verbetering van de chi-
rurgische resultaten en het vermijden van chronische pijnklachten, een veelbelovende
toepassing van deze techniek kunnen zijn.
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